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Malignant melanoma is a very metastatic and therapy resistant disease, with few 
therapeutic options in advanced stages. An abnormal apoptosis pathway is considered 
to contribute substantially to the resistance observed in melanoma patients. In this 
study, “close-to-patient” melanoma cell models: adherent monolayers in serum-
containing media and non-adherent spheroids in stem cell media (which supposedly 
selects for stem-like melanoma initiating cells), were compared with respect to: the 
expression of anti-apoptotic molecules from the Inhibitors of Apoptosis Proteins 
(IAP) family; and sensitivity to the treatment with Tumor Necrosis Factor (TNF) - 
Related Apoptosis Inducing Ligand (TRAIL), acting through death receptor 4 and 5 
(DR4 and DR5), alone or in combination with siRNA-mediated down-regulation of 
IAPs. Spheroids demonstrated a higher expression of IAPs (in 8 from 15 studied 
cases), where the IAP livin was up-regulated the most. Also a tendency for up-
regulation of DR5 was shown, and the spheroid cells were more sensitive to the DR5-
mediated treatment than the monolayer cells, indicating that this strategy might affect 
tumor initiating cells present in melanoma spheres. The treatment via DR4 had only a 
negligible effect. Although down-regulation of XIAP showed a small additive effect, 
the contribution of the XIAP or survivin knock-down to the reduced cell viability or 
spheroid forming capacity, was very low.  
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1.1 Cancer  
In 2007 the Word Health Organization reported 7.9 million deaths globally from 
cancer. Cancer Registry of Norway estimates that one out of three Norwegians will 
be diagnosed with cancer before the age of 75, and that the overall survival rate after 
5 years averagely would be ~60% 
1
.  
When a cell obtains genetic or epigenetic changes that result in proliferation without 
normal restraints, or reduced ability to die, it will be defined as a cancer cell
2
. Cancer 
cells may invade nearby tissue, and they may spread through the bloodstream and 
lymphatic system to other parts of the body. Generally, several independent 
alterations, like loss of tumor suppressor genes or gain of oncogenes, are needed to 
form a cancer cell, consistent with, that cancer incidence correlates with age. Both 
inheritable factors and environmental factors (like chemical carcinogens, ionizing 
radiation and virus) could influence tumor formation
2,3
. However, 80-90% of cancer 
incidences are thought to result from environmental  factors (www.kreft.no). 
A benign tumor consists of abnormal cells growing in a distinct area incorporated in a 
connective tissue, and is usually curable by surgery. If a tumor consists of cells with 
invasive properties, it is defined as malignant, and, if not treated, might form 
metastases at a distant site, i.e. a secondary tumor. A metastatic cancer is often related 
to a poor outcome
1,2
.  
Standard therapies of cancer like radiotherapy and chemotherapy, often do not lead to 
cure due to the presence of therapy resistant cancer cells within a tumor (FIG. 1.1). 
This will often result in a relapse and formation of a new more resistant tumor. 
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FIG. 1.1: A tumor often consists of heterogeneous cells, where some cells are resistant to 
therapy and may lead to relapse, forming a new therapy resistant tumor after therapy 
completion. 
1.1.1 Melanoma 
Melanoma is a cancer deriving from melanocytes, the pigment melanin producing 
cells found predominantly in skin
4,5
. Under normal conditions, homeostasis of 
melanocytes is tightly regulated by keratinocytes. UV radiation triggers keratinocytic 
stimulation of melanocytes, leading to their proliferation, differentiation and melanin 
production
5
. In melanoma, this regulation is lost. The classical melanoma progression 
model emphasizes a stepwise transformation of normal melanocytes to malignant 
melanoma through several intermediate stages as illustrated in FIG. 1.2
4,6
.  
Melanoma is the most deadly form of skin cancer and it is considered to be among 
the most aggressive types of human cancer. The incidence of melanoma is rising in 
industrialized countries, leading to more than 1 100 Norwegians diagnosed with this 
disease every year
1,4
. If melanoma is discovered in an early phase, removal of 
cancerous tissue by surgery is very effective, reflected by good prognosis of 90% 
survival 5 years after diagnosis (oncolex.no). However, melanoma is highly 
metastatic and metastasized cells are markedly resistant against all chemotherapeutic 
drugs
4
. The metastatic disease is incurable in most patients. The median survival of 
these patients is only 6 months and the 5-year survival rate less than 5 % 
4
. The 
alkylating agent Dacarbazine (DTIC), is the only chemotherapy approved in Norway 





FIG. 1.2: A classical model of melanoma progression through several steps: a benign nevus 
followed by phases invading the basement membrane, resulting in aggressive metastatic 
melanoma.   
Various combinatorial treatments towards metastatic melanoma are tested in clinical 
trials, often demonstrated to improve the tumor response rate, but unfortunately not 
the overall survival of the patient
8,9
. One such promising treatment involves the anti-
apoptotic protein Bcl-2 (FIG. 1.4), which is involved in a large trial, which will be 
finish in 2011 (www.clinicaltrials.gov). A lot of poor responses in clinical trials could 
be related to the extremely low threshold to give permission for new treatment 
modalities in melanoma trials
9
. This is of course related to the desperate need for 
better therapy for patients in advanced stages. A more personalized treatment would 
very likely be more efficient than therapies used today. If scientists find markers 
describing cancer stem cells in melanoma (discussed in chapter 1.1.2), this could be 
the new angle of attack, and contribute to the discovery of novel treatments.  
1.1.2 Tumor-initiating cells (Cancer stem cells) 
Cells constituting a tumor are heterogeneous, they have different tumor initiating 
abilities, metastatic potential, sensitivity to therapies etc.
10
. Hence, identification and 
targeting of the most tumorigenic cells are of great importance in cancer therapy. 
Traditionally, cancer development has been explained by the clonal evolution model 
(shown in FIG. 1.3 A) postulating that this is a random process where all cells have 
an equal probability to be a tumor initiating cell. Selection of the tumorigenic cell 





Lately it has been shown that some cancer cells show properties of normal stem cells, 
e.g.: they can self renew, differentiate and have enhanced resistance mechanisms, 
(reviewed in
12,13,14
). It has been hypothesized that such rare tumor cells with stem cell 
properties, often called cancer stem cells (CSC), are responsible for tumor initiation 
(FIG. 1.3 B). Post-therapy tumor relapse (as shown in FIG. 1.1) or development of 
metastases also might originate from a CSC, though not necessarily identical to the 






FIG. 1.3: The two models used to explain tumor heterogeneity and proliferation are (A) the 
clonal evolution model and (B) the cancer stem cell model. The clonal evolution model is 
based on a random selection of the cell best fitted for the given microenvironment. The 
cancer stem cell model is based on a non-random cell with certain predetermined properties 
(stem cell properties) necessarily for tumor initiation. Tumor cells with different phenotypes 
are presented in different colors, a curved arrow indicates self renewal properties, and an 
oncogenic hit is marked with a lightning. 
Malignant melanoma cells resemble stem cells in many ways, i.e. they show great 
therapeutic resistance and easy adaptation to various microenvironments (metastatic 
site), are very heterogeneous and plastic, can differentiate into multiple lineages and 
expresses developmental genes. Therefore, it was suggested that stem-like cells might 
be present in melanoma and might play a role in its progression
17,18
. Several studies 
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have attempted to identify candidate melanoma CSC, and cell surface molecules like 
CD20, CD133, ABCG2 or ABCG5 were suggested as CSC markers, but no 
consistent conclusions have been drawn yet
19,20,21,15,22
. Furthermore, it has been 
shown that by growing cells in media without serum, (which supports sphere-
formation), the media will enrich for stem cell properties, and consequently, CSC
23
 
(described further in chapter 1.3.1).  
Given that the clonal evolution model is the basis for most existing therapies, which 
targets the bulk of a tumor, and that relapse after treatment still is a problem in most 
solid cancers, CSC theory could represent a more accurate foundation for drug 
development. However, targeting CSC is not an easy task, and it has been reported 
that majority of conventional therapies do not affect stem-like tumor cells
24
. Though, 
several therapeutic approaches targeting CSC have been tested. In melanoma, e.g. 
treatment with monoclonal Ab against the multidrug resistant protein ABCB5, which 
according to Schatton et. al. identifies melanoma initiating cells, resulted in tumor-
inhibitory effects in vivo
15
. Thus, growing evidence indicates that it might be 
important to focus on the tumor initiating cells when creating future therapies, and, 
therefore more knowledge about these cells is needed.  
1.2 Apoptosis 
Apoptosis is defined as controlled cell death, and many therapeutic anti-cancer 
strategies are based on this process (reviewed by e.g. Jacobson et. al.
25
). Apoptosis 
leads to shrinkage and fragmentation of the cell and the nucleus, degradation of  
chromosomal DNA by e.g. caspase activated DNase (CAD) 
26
, and cytoskeleton 







FIG. 1.4: The main actors in the intrinsic and extrinsic apoptotic pathway, here illustrated 
by receptor induced apoptosis by TRAIL. TRAIL binding to DR4 or DR5 leads to receptor 
trimerization, Fas-associated death domain protein (FADD) binding, and pro-caspase 8 
association. The complex formed is called death-inducing signalling complex (DISC). In 
DISC, pro-caspase 8 is cleaved to form caspase 8, which cleaves pro-caspase 3 to active 
caspase 3, resulting in apoptosis. IAPs inhibit the apoptotic stimuli primarily by blocking 
active caspase 3 and/or caspase 9. Caspase 8 also cleaves Bid to active truncated, t- Bid, 
which links the extrinsic and intrinsic pathway together. Cytochrome c and DIABLO release 
from the mitochondria may result from e.g. t-Bid or Bax stimulation, and could be inhibited 
by anti-apoptotic members of the Bcl-2 family. Pro-caspase 9 associates with cytosolic 
cytochrome c and Apaf-1 to form the apoptosome. The apoptosome processes pro-caspase 9 
into the active version of caspase 9, which further stimulate pro-caspase 3 cleavage. The 
intrinsic pathway could be activated via p53 by e.g. DNA damage. See chapter 1.2.1 and 
1.2.2 for relevant abbreviations.   
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Cystein proteases called caspases, are the central players in the apoptotic pathway, 
where they upon activation cleaves nearly 100 different proteins in the cytoplasm 
(reviewed by Hengartner
28
 ). Caspases are produced as zymogens and becomes 
processed in the cytoplasm by other caspases or by autocatalysis. The initiator 
caspases includes caspase 8 and 9, and are activated by cellular stress, like death 
receptor activation (extrinsic pathway), DNA damage (intrinsic pathway) or ER stress 
28,29
. Executor caspases, like caspase 3, are activated by the initiator caspases, and are 
responsible for cleavage of downstream effectors. FIG. 1.4 presents an overview of 
the apoptotic pathway, focusing on the proteins relevant in this study. The apoptotic 
pathway is demonstrated to be important, when understanding malignant melanoma: 
e.g. the caspase 8 inhibitor cFLIP is up-regulated in malignant melanoma, when 
compared to benign nevus
30
. 
1.2.1 TRAIL induced apoptosis via death receptor 4 and 5 
A member of the tumor necrosis factor (TNF) super family, called TNF related 
apoptosis inducing ligand (TRAIL), was discovered in 1995 by the help of 
bioinformatics
31
. This membrane-bound ligand is expressed by cells in the immune 
system
32
, like natural killer cells, B and T lymphocytes. The natural target cell of 
TRAIL is oncogenic cells or pathogen infected cells, and was therefore early posted 
to have promising effects in cancer therapy. TRAIL binds to receptors on the target 
cell (FIG. 1.5), resulting in apoptosis induction by signalling through the extrinsic 
pathway
31
, as illustrated in FIG. 1.4. TRAIL is able to bind five different receptors. 
death receptor 4 and 5 (DR4 and DR5) are the functional transducers in the target 
cell, which need TRAIL binding and receptor trimerization to be active 
33,34
. The 
decoy receptors DcR1 and DcR2 and the plasma protein osteoprotegerin can 
associate with TRAIL, but can not activate the apoptotic pathway, and have a more 






FIG. 1.5: Receptors binding TRAIL presented in their monomeric form. DR4 and DR5 have 
a functional cytoplasmic death domain, while the decoy receptors DcR1, DcR2 and 
osteoprotegerin are unable to signal through the extrinsic apoptosis pathway. 
DR4 and DR5 are reported to be up-regulated in several cancer tissue
38
, whereas the 
receptor deficient mice are proven to be more exposed to lymph node metastasis
39
. 
Despite DR4 and/or DR5 expression in cancer cells, resistance to TRAIL is reported 
by several groups, and is often a result of alterations in the extrinsic pathway
40
. In 
melanoma, about one third of melanoma cell lines are TRAIL resistant, despite high 
levels of DR5
41,42
. Generally melanoma has a higher level of DR5 then DR4
43
, and a 
patient has a greater chance of disease free survival if DR5 positive melanoma cells 
are greater than 90%
44
. Primary melanomas show an increased DR5 level when 
compared to nevi or metastatic tissue, indicating that DR5 down-regulation could be 
involved in therapy resistance in metastatic tissue
44
.  
There are several options for apoptosis induction via DR4 or DR5. Recombinant 
TRAIL peptides, proto-agonistic Ab (Ab activating both DR4 and DR5), TRAIL 
receptor antibodies and gene therapy vectors (i.e. plasmids, adenovirus and adeno-
associated virus (AAV)) coding for TRAIL, have been tested in vitro and in vivo, 
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alone or in combination with other therapeutic substances, as reviewed in 
45,46
. In this 
study, TRAIL receptor Abs from Human Genome Sciences (HGS), (HGS-ETR 1 
(Mapatumumab) directed towards DR4, and HGS-ETR 2 (Lexatumumab) directed 
towards DR5), are employed to initiate the extrinsic pathway in melanoma cells. 
Clinical studies so far, indicate that TRAIL-mediated DR4/DR5 activation alone 
could result in longer progression free survival, but not longer overall survival in 
several cancer types. Thus, a combination of drugs is probably needed to achieve a 
complete treatment response.   
1.2.2 Inhibitors of Apoptosis Proteins 
In 1993 Crook et al. discovered a baculovirus gene that coded for a protein able to 
inhibit apoptosis in insect cells, i.e. inhibitor of apoptosis protein (IAP)
47
. To this 
date, eight human homologs are identified as baculovirus IAP repeat containing 




. In addition to 




Table 1.1: Overview of the IAPs used in this study with BIRC pseudonyms, number of amino 
acids in the main splicing form, and domains essential for their function. All IAPs contain at 
least one baculovirus IAP repeat (BIR) domain. Livin, XIAP, cIAP-1and cIAP-2 contains a 
domain called really interesting new gene (RING), and cIAP-1 and cIAP-2 has a caspase-
recruitment domain (CARD). (Nucleotide-binding and oligomerization domain (NOD), 
leucin-rich repeat (LRR) domain, ubiquitin-conjugation (UBC) domain48.) See text for 




The BIR domains function primarily in protein-protein interactions between the IAPs, 
or between an IAP and a caspase in the apoptotic pathway, resulting in inhibition of 
caspase activity (FIG. 1.4). Neuronal apoptosis inhibitory protein (NAIP) and BIR 
repeat-containing ubiquitin-conjugating enzyme (Bruce) contain additional domains 
not essential in the apoptotic process. 
The apoptotic roles of the IAPs are not fully understood, nevertheless, X-linked IAP 
(XIAP) seems to be one of the central players with direct caspase 3, 7 and 9 blocking 
capacity
52
. The other IAPs seem to inhibit the caspases indirectly by releasing XIAP 
from IAP inhibitors as DIABLO, or marking the caspases for protein degradation by 
their E3 ubiquitin ligase domain, RING. The RING containing IAPs could also 
regulate each others levels, as seen for e.g. cellular IAP-2  (cIAP-2) and XIAP 
degradation by cellular IAP-1 (cIAP-1)
53,54
. IAPs have also been shown to participate 
in signalling associated with cell division and signal transduction
49
. Apoptosis 
resistance in cancer is in some cases influenced by IAP
48
, and several cancers are 
reported to have an elevated IAP level
55
.  
Several studies have reported about survivin expression in all stages of melanoma, 
whereas no survivin was expressed in normal melanocytes
56,57
. This matches 
observations where survivin level is significantly correlated with disease outcome in 
melanoma patients
58,59
. Several studies show that nuclear survivin detection in 
melanoma can be used as a factor to predict poor survival
60,61,62
. 
By down-regulating XIAP and inducing apoptosis by TRAIL, Chawala-Sarkar et al. 
demonstrated apoptotic induction in originally TRAIL resistant melanoma cells in 
vitro, and Vogler et al. induced apoptosis in pancreatic cancer cells in mice 
models
63,64
. Both XIAP and survivin down-regulation in cancer are under clinical 
investigation, as reviewed by LaCasse et al. 2008, where phase 2 studies show 
promising results so far
48
. A great amount of evidence indicate that IAP inhibition 
have the potential as a good therapeutic target in cancer. 
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1.3 Methodological background 
1.3.1 Model systems 
In vitro cell cultures like adherent monolayers in serum-containing media is a usual 
model system used in cancer research. However, long-term culturing under such 
conditions will lead to cell differentiation and adaptation to the two-dimensional (2D) 
growth, thus these cells might have a different phenotype/genotype than the original 
cells taken from the patient
23
. Culturing the cells as non-adherent spheroids in serum-
free media supplemented with growth factors (i.e. media for normal embryogenic 
stem cells), preserve the phenotype/genotype of the original tumor
65,23
, suggesting 
that, spheroids are a better model to mimic clinical samples
66
. Furthermore, it has 
been shown, that spheroid cultures allow the persistence of stem cell properties, and, 
consequently, spheroids seem to be enriched for CSC
23,65
. Fang et. al. has shown that 
melanoma spheroids contained cells with stem cell properties and, that spheroid cells 
demonstrated higher tumorigenic abilities in mice than the monolayer cells
19
. An 
independent study by Prasmickaite et. al. (manuscript in preparation), comparing 
tumor initiating abilities of monolayer and spheroid cells from “close-to-patient” cell 
cultures called Melmets (FIG. 1.6), generally confirmed the observations by Fang et. 
al. All together, this encouraged the here presented study on therapy resistance 
associated molecules, IAPs, and response to pro-apoptotic stimulus via DR4 and DR5 
in melanoma spheroids versus monolayers.  
In the present study, three different Melmet cell lines were studied: Melmet 1, 
Melmet 5 and Melmet 79. Melmet cultures represent “close-to-patient” early-passage 
material and, therefore, are superior to the long-established commercially available 
melanoma cell lines cultured in vitro for years, when studying melanoma resistance 




FIG. 1.6: Efficiency of tumor initiation in nude mice by Melmet 1, Melmet 5 and Melmet 79, 
respectively. Number of cells per injection is plotted against percent tumor formation. 
Monolayer is abbreviated (mono) and spheroids (sph). (Figure borrowed with permission 
from Prasmickaite).   
The Melmets were tested for the sensitivity to the reference chemotherapeutic drug 
DTIC, and demonstrated a low response when grown as monolayers (FIG. 1.7, 
Engesæter, unpublished), reflecting the true chemo-resistant nature of malignant 
melanoma. 
 
FIG. 1.7: Melmet 1, 5 and 79 treated with DTIC at the concentrations 50µg/ml and 
100µg/ml. Cell viability are related to untreated control cells. (Figure borrowed with 
permission from Engesæter).   
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1.3.2 Oligonucleotide transfection 
There are several ways to introduce nucleotides transiently into cells in vitro, 
reviewed by Colosimo et. al.
67
. Protein up-regulation could be achieved by e.g. 
introduction of mRNA or DNA, and protein down-regulation could result from e.g. 
introduction of siRNA (described in chapter 1.3.3). Oligonucleotides by themselves 
are poorly taken up by the cells. To improve the uptake, the oligonucleotides are 
often complexed with various transfection agents. Liposomes, like Lipofectamine 
2000
TM
 and Lipofectamine RNAi MAX
TM
, in complex with oligonucleotides are 
generally effectively taken up by eukaryotic cells by endocytosis and/or membrane 
fusion
68
. Disadvantages of these cationic lipids are a varying degree of toxicity
69
.   
1.3.3 mRNA down-regulation by RNA interference 
RNA interference (RNAi) was revealed in 1998 by Fire and Mello
70
. By using 
Caenorhabditis elegans as model system, they demonstrated that by introducing 
double stranded RNA, with a homologous sequence to an mRNA, this specific 
mRNA would be degraded. This system is now discovered in almost all eukaryotes, 
and has been associated with functions as viral defence, mobile element silencing, 
mRNA regulation (by microRNA) and chromatin condensing
71
.  
The general mechanism of the RNAi system used by endogenous gene regulatory 
RNA is reviewed in
72,73
. When the mechanism is exploited artificially by small 
interfering RNA (siRNA), the antisense strand of siRNA incorporates into the RNA-
induced silencing complex (RISC) (FIG. 1.8). RISC associated proteins perform 





FIG. 1.8: When the RNAi mechanism is used artificially, the antisense strand from the siRNA 
will be incorporated into RISC. When the antisense sequence is 100% complimentary to an 
mRNA molecule, the endonuclease activity of RISC cleaves the target mRNA.  
The RNAi mechanism is an excellent tool in research, giving the opportunity to 
down-regulate the expression from specific genes and thereafter evaluating 
phenotypic effects (reverse genetics). There are also reports from in vivo studies, 
highlighting a promising future for siRNA as therapy in humans
74,75
. In cancer 
research, RNAi could theoretically be used to knock-down oncogenes, though, 
problems related to stability in blood and delivery to target cells, limits the practical 
benefit to this date. Clinical trials using siRNA were first initiated in 2004, and in 
2008, several trials were ongoing, e.g. two phase II studies involving an eye disease
76
. 
Given the theoretical potential and the rapid developme nt in the field, the RNAi 
mechanism will most likely be central in future therapy of human diseases. 
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Aim of the study 
The overall aim of the present study was to characterize “close-to-patient” malignant 
melanoma cell cultures, Melmets, in respect to apoptotic resistance-associated 
molecules, IAPs, and pro-apoptotic molecules, DR4 and DR5. Furthermore the effect 
of a therapeutic strategy based on RNAi mediated down-regulation of IAPs combined 
with activators of the apoptotic pathway via DR4 and DR5 was investigated. The 
focus of the study was a comparison of different in vitro Melmet models: monolayers 
versus spheroids (supposedly enriched for melanoma stem cells), with regard to: 
1) Expression of IAPs (survivin, livin, XIAP, cIAP-1 and cIAP-2) at protein and 
mRNA level 
2)  Expression of DR4 and DR5 at protein level  
3) Cell viability and spheroid formation after treatment with TRAIL receptor 
antibodies targeting DR4 and DR5 
4) Cell viability and spheroid formation after treatment with TRAIL receptor 
antibodies in combination with siRNA targeting selected IAPs: XIAP or survivin. 
By studying these aspects, we aim to reveal resistance-associated properties of 
aggressive melanoma cells and to get an implication for future therapeutic strategies. 
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2. Materials and methods 
2.1 Cell lines 
Metastatic melanoma cell lines, generally named Melmets, were established from 
biopsies of metastatic melanoma patients at the department of Tumor Biology, the 
Norwegian Radiumhospital. The establishment of Melmet 1, Melmet 5 and Melmet 
79 cultures as monolayers and spheroids is described by Prasmickaite et . al. 
(manuscript in preparation)(background information summarized in table 1.2). In 
brief, monolayer cultures were established isolating melanoma cells by the 
immunomagnetic bead-based method as described below (chapter 2.3), and growing 
the isolated cells in serum-containing media RPMI ++ (described in chapter 2.2). 
Melmet 1 and Melmet 5 spheroid cultures were established from the low-passage 
(passage 9 and 8, respectively) corresponding monolayer cultures, growing the cells 
in the specialized serum-free human Embryonic Stem Cell Media 4 (hESCM4) 
(composition described in the appendix), which supports sphere formation
19
. The 
Melmet 79 spheroid culture was established directly from the lymph node biopsy, 
omitting the immunomagnetic bead-based step and the monolayer step, but culturing 
the cells directly in hESCM4.   




2.2 General cell work. 
All reagents, materials and instruments used in cell related work are listed in table 
2.2. Cells cultured as monolayers were grown in cell flasks in RPMI 1640 media 
supplemented with 8% FCS and 2mM L-glutamine (further referred as “RPMI++”). 
Cells cultured as spheroids were grown in petridishes in hESCM4. Cells were 
cultured in an antibiotic free environment, in a 5.0% CO2 atmosphere at 37°C. EDTA 
was used to detach monolayer cells from a flask, and to disintegrate spheroids into 
single cells. When making a new passage of spheroids, single cells were seeded at a 
low concentration (i.e. 1000 cells/ml), to make sure the spheroids formed originate 
from one cell, and not a cell aggregate. 2µl trypanblue was added to 10µl cell 
suspension to label dead cells so that only the viable cells were counted. The cells 
were tested for mycoplasma infection every sixth week. All cell cultures used in this 
work were mycoplasma-free. 
Dry pellets were made for various analyses described in chapter 2.4 and 2.5. When 
dry cell pellet was made from monolayer cultures, the cells were washed once in cold 
PBS. New PBS was added, and a cell scrape was used to harvest the cells. Cell 
suspension was centrifuged for 8min at 1200rpm at 4°C. Supernatant was removed 
and the dry cell pellet was stored at -80°C. 
When dry cell pellet was made from spheroid cultures, the spheroids were 
sedimented, the spheroid pellet was washed once with cold PBS and disintegrated 
into single cells with 50µl EDTA. 5ml RPMI++ was added to the single cell 
suspension which was centrifuged for 8min at 1200rpm. Cold PBS was added to the 
cell pellet and centrifuged again for 8min at 1200rpm. Supernatant was removed and 










Materials/instruments: Company: Cat#: 
12 well plates NUNC
TM
, Denmark 150200 
15 ml tubes Sarstedt, Nümbrecht 62.554.502 
2, 5, 10 and 25ml pipettes Sarstedt, Nümbrecht  
50 ml tubes Sarstedt, Nümbrecht 62.547.254 
6 well plates NUNC
TM
, Denmark 150239 
96 well plates BD Falcon
TM
, USA  
basic Fibroblastic Growth Factor (bFGF) Invitrogen 13256-029 
Biofuge primoR, for eppendorf tubes Heraeus  
Bovine Serum Albumin (BSA) Sigma Aldrich, Switzerland A-3059 
Cell flasks, EasYFlasks
TM
  with filter NUNC
TM
, Denmark  
Cell scraper Sarstedt, Nümbrecht 83.1831 
Centrifuge 5810R, for 10ml tubes Eppendorf  
EDTA, Versene BioWittaker
®
, Belgium 12-711A 
Eppendorf tubes Trefflab, Switzerland  
Fetal Calf Serum (FCS) PAA Laboratories, Austria  A15-101 
Filter tips Molecular Bio Products®  
Knock Out
TM
 DMEM-F12 Gibco®, Invitrogen 12660 
KnockOut
TM
 Serum Replacer  Invitrogen 10828-028 
L-Glutamine GibcoBRL, UK 25030 
Microscope for general cell work Leica DMIL  
Mouse Embryonic Fibroblast, P3 strain CF-1 Chemicon Embryomax® PMEF-CF 
Mycoplasma PCR detection kit Venor®GeM, Minerva biolabs 11-1025 
Non essential amino acids Gibco®, Invitrogen 11140-035 
Phosphate Buffered Saline (PBS) BioWittaker
®
, Belgium 17-516F 
RPMI 1640 media BioWittaker
®
, Belgium 12-167 
Trypanblue Sigma Aldrich, Switzerland T-0887 
β-mercaptoethanol Sigma Aldrich, Switzerland 7522 
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2.3   Isolation of tumor cells with immunomagnetic beads 
The immunomagnetic bead-based technique has been used for isolation of metastatic 
melanoma cells from patient biopsies and from various organs (like brain, lung, bone 
marrow, spinal cord and eyes) of rats with experimental metastases. Materials and 
instruments used for immunomagnetic isolation of tumor cells are listed in table 2.3. 
Magnetic beads were coated with the 9.2.27 Ab, which binds to the High Molecular 
Weight melanoma-associated antigen, HMW-MAA, and in this way, allows 
separation of melanoma cells from the rest of the cells by using a magnet
77,78
. PBS 
supplemented with 1% HSA, (to prevent unspecific binding, further referred as 
“PBS+”) was used in all steps when isolating cells with immunomagnetic beads. All 
the procedures were performed at 4
o
C. Lymph node biopsies or samples from rat 
brain, lung or eyes were disintegrated into small pieces in cold PBS+ by using 
scalpels, and filtered through a 70µm filter to remove big clumps. Cells from rat tibia 
or columna were isolated by flushing these organs with PBS+ by the help of a syringe 
and a needle. The obtained cell suspension was filtered as described above and 
centrifuged for 5min at 1100rpm. Supernatant was discarded and the ACK Lysing 
buffer was added to the cell pellet at the volume ratio of 1:1 to disrupt red blood cells. 
After incubation for approximately 2-3min, 10ml of cold PBS+ was added before 
centrifugation for 5min at 1100rpm. Pellet was resuspended in 0.5ml PBS+ and 
mixed with 25µl of a magnetic bead suspension containing 2x10
8
 antibody coated 
beads/ml. It is important to have an excess of beads with respect to the number of 
cells. After incubation under constant rotation for 30min at 4°C, 10µl of suspension 
was dripped onto a cover slip glass and examined under a microscope. A cell with ≥5 




FIG. 2.1: Melanoma cells binding 9.2.27-coated magnetic beads. 
To separate melanoma cells from the rest of the cells, the tube with the cell and bead 
suspension was put into a special holder with a magnet, and the supernatant was 
discarded. The magnet-bound cells were gently washed with 500µl PBS+, and 
resuspended in appropriate buffer. Then the tube with the “cells + beads” was taken 
of the magnet. The cells binding the beads were further used for preparation either 
protein lysate or RNA lysate as described below. To make protein lysate for protein 
analysis, 100µl of lysis buffer with inhibitors (specified in appendix, materials listed 
in chapter 2.4.2) was added to the “cells + beads”, and the resulting suspension was 
put in -80°C. After thawing, the beads were removed with the magnet as described 
above, and the remaining lysate was sonicated (as described in chapter 2.4.2). To 
make RNA lysate for gene expression analysis, RNA lysate buffer containing β-
mercaptoethanol was added to the “cells + beads”, and the beads were discarded by 
the help of the magnet. The obtained lysate was used for isolation of RNA as 




Table 2.3: Materials and instruments used when isolating tumor cells with the magnetic 
bead technique. 
Materials/Instruments: Company: Cat#: 
ACK lysing buffer BioWhittaker®, Lonza 10-548E 
Cell Strainer, 70µm filter BD Falcon
TM
, USA 352340 
Human Serum Albumin (HSA)  Octapharma, Sweden (MT.nr.) 03-2156 




Sheep anti-mouse(SAM) M450 IgG magnetic beads  Dyn l, Invitrogen 110.31 
Syringes and needles Tamro  
2.4 Protein analysis by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blotting 
SDS-PAGE is a method based on separation of proteins based on their size: a large 
protein will travel a shorter distance than a smaller protein in an unfolded state in a 
given polyacrylamide gel. Western blotting is a method for transmitting proteins from 
a gel to a membrane using an electrical gradient. The proteins of interest are 
visualized by using specific antibodies. FIG. 2.2 illustrates a theoretical overview of 
SDS-PAGE and western blotting. SDS-PAGE was preformed by using either home-
made gels prepared with reagents from BIO-RAD (see chapter 2.4.1) or commercial 
gels from Invitrogen. Materials used to make general buffers are listed in table 2.4.  
Table 2.4: Materials used to make general buffers used in SDS-PAGE and western blot. 
Materials: Company: Cat#: 
Glycin Merck KGaA, Germany 104201 
NaCl Merck KGaA, Germany 106404 
Sodium Dodecyl Sulfate (SDS) 20% BIO-RAD laboratories 161-0416 
Tris HCl Merck KGaA, Germany 108382 
Tween 20 Merck KGaA, Germany 822184 





FIG. 2.2: Theoretical overview of SDS-PAGE and western blot. Positive and negative circles 
illustrate an electrical gradient. Different chapters indicated on the left side, describe the 
theory and performance in more detail. (Ab – antibody, HRP – Horseradish peroxidase). 
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2.4.1 Gel casting: home-made gels 
The gels consist of two parts: the lower separating part and the upper concentrating 
part. The gel-parts were prepared from materials in amounts listed in table 2.5. 
Materials and instruments used in gel casting are listed in table 2.6.  
First the separating gel, containing 8% acryl amide, was mixed and poured into an 
assembled gel casting apparatus. After approximately 30min, the gel was 
polymerized, and a concentrating gel containing 5% acryl amide, was poured on top 
of the separating gel. The concentrating gel was left for polymerization for 
approximately 30min.   
 
Table 2.5: Volumes of different materials used in SDS-PAGE gel casting.  
Material: Separating gel: Concentrating gel: 
Acryl amide/bis 5.4ml 1.34ml 
Tris pH 8.8 7.5ml - 
Tris pH 6.8 - 1ml 
SDS 100µl 40µl 
APS 200µl 80µl 
ddH2O 6.7ml 5.4ml 
TEMED 12µl 8µl 
 
 





Acryl amide/bis 30% BIO-RAD laboratories 161-0158 
Ammonium PerSulfate (APS) 10% BIO-RAD laboratories 161-0700 
Gel casting equipment (Mini Trans-Blot Cell) BIO-RAD laboratories 170-3935 




To get access to all proteins in a cell, the cells must be lysed. Materials and 
instruments used for lysation and when performing SDS-PAGE, are listed in table 
2.7. A lysis buffer with protease inhibitors was added to cell pellets (harvested as in 
chapter 2.2), and incubated on ice for an hour, vortexing every 15min. The samples 
were then sonicated 3 times for 5 seconds and centrifuged for 15min at 12000rpm at 
4°C. The supernatant, i.e. the cell lysate, was transferred to a new tube and frozen at -
80°C. 
The protein concentration of the cell lysate was determined by using the Bio-Rad 
protein assay in accordance with the producer recommendations. The kit is a 
colorimetric assay that is based on the color change of Coomassie Brilliant Blue dye 
in response to various concentrations of proteins. The absorption was measured at 
595nm and is proportional to the amount of the protein in the sample. The protein 
concentration was calculated from a standard curve based on absorption of the known 
amounts of protein in Protein standard 1.  
When home-made gels were used, 4µl of 6x sample buffer, to denature the proteins 
and give them a negative charge, were added to 40µg protein lysate. Lysis buffer 
without inhibitors (specified in appendix) was used to dilute samples to a total sample 
volume of 20µl. Samples were denatured at 95°C for 5min before application on a 
gel.  In parallel, 4µl sample buffer was added to 6µl of the Standard ladder, denatured 
as above and applied in at least one well. A ladder contains proteins with known 
molecular weight, and is used to confirm that the band detected, has approximately 
the same weight as the protein of interest. The gel was run in a running buffer 
(specified in appendix) for approximately 2 hours at 30mA. 
When commercial gels were used 1µl of 10x reducing agent and 2.5µl of 6x LDS 
sample buffer was added to 22µg protein. ddH2O was used to dilute samples into a 
total sample volume of 10µl. Samples were denatured at 70°C for 10min before 
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application on a gel. 2.5µl See blue standard was applied in at least one well. The gel 
was run in 1x MOPS for approximately 60min at 150V, to obtain good separation of 
the proteins.  




Aprotinin Sigma Aldrich, Switzerland A4529 
Bromophenol blue Merck, Germany 8122 
Glycerol Sigma Aldrich, Switzerland G7893  
Leupeptine Sigma Aldrich, Switzerland L2884 
NONIDET®P40  Usb, corporation, USA 19628 
Bio-Rad protein assay kit  BIO-RAD laboratories 500-0006 
NuPAGE® LDS sample buffer (4x) Invitrogen NP0008 
NuPAGE® MOPS SDS Running Buffer (20x) Invitrogen NP0001-02 
NuPAGE® Novex® 4-12% Bis-Tris Midi Gel Invitrogen WG1403BOX 
NuPAGE® Sample Reducing agent (10x) Invitrogen NP0004 
Pepstatine A Sigma Aldrich, Switzerland P4265 
Phenylmethanesulfonylfluoride (PMSF) Sigma Aldrich, Switzerland P7626 
Precision Plus Protein
TM
 Dual Color Standards BIO-RAD laboratories 161-0374 
Protein standard 1.  BIO-RAD laboratories 500-0005 
See Blue® Plus 2 Prestained Standard (1x) Invitrogen LC5925 
β-mercaptoethanol Sigma Aldrich, Switzerland M7522 
Ultrasonic Homogenisator/ Sonicator   
2.4.3 Western blotting 
The separated proteins were transferred from the gel to a filter, before protein 
detection using Abs. All materials and instruments used for western blotting are listed 
in table 2.8. Home-made gels were washed in Bjerrum-Scäfer-Nilsen (BSN) buffer 
(specified in appendix) for 10min. In parallel, an Immobilon-P Transfer Membrane 
was activated in methanol, before a wash in ddH2O, and 10min of neutralizing wash 
in the BSN buffer. All pads and filter papers were soaked in the BSN buffer. A gel-




FIG. 2.3: Assembly of pads, filter papers, a membrane and a gel. 
Home-made gels were blotted in the BSN buffer with a cooler element and a 
magnetic stirrer over night at 4°C at 30V, or at room temperature for 90min at 90V. 
To visualize the protein bands, the membrane was thereafter incubated in amidoblack 
solution (specified in appendix) for 5min, and washed in destaining solution 
(specified in appendix) for 2 x 10min. Since amidoblack stains all proteins in the 
membrane, it is possible to get an indication about the quality of a loading and a 
transfer (see FIG. 2.4). 
 
FIG. 2.4: An example of a filter stained with amidoblack, where 9 samples and one standard 
(the right line) were applied. 
Commercial gels were blotted onto a nitrocellulose membrane in iBlot
TM
 blotting 
apparatus from Invitrogen for 10min, in accordance with the protocol of the supplier. 
Since the membrane used with commercial gels is nitrocellulose-based, it could not 
be stained with the methanol-containing amidoblack solution, since methanol would 




Table 2.8: Materials and instruments used in western blotting. 
Materials/instruments: Company: Cat#: 
Acetic Acid Merck, Germany 100063 
Blotting equipment BIORAD laboratories 170-3935 
Gel Blotting paper/ Whatman paper Schleicher & Schuell 10426694 
iBlot
TM
 blotting machine Invitrogen
TM
 IB1001EU 
iBlotTM Gel Transfer Stacks Nitrocellulose Invitrogen
TM
 IB3010-01 
Immobilon-P Transfer Membrane Millipore IPVH00010 
Methanol VWK 20834-325 
Naphtol Blue Black Sigma Aldrich, Switzerland N-3005 
2.4.4 Incubation with antibodies 
To detect the protein of interest, the filters were incubated with different primary Abs 
specific for the various proteins studied. Secondary Abs link primary Abs to a 
detectable signal (explained in chapter 2.4.5). This step of the western analysis is 
identical for both gel-types.  
Table 2.9: Antibodies used for protein detection, western analysis.  
 
Ab dilutions, buffer types and composition of the milk solutions were optimized for 
each Ab and are listed in the table 2.9, and specified in the appendix. Generally, a 
membrane was blocked in a milk solution for one hour and incubated with a primary 
36 
 
Ab over night at 4°C. After 3 x 10min washing in the buffer, the membrane was 
incubated with a secondary Ab for one hour at room temperature. Then the membrane 
was washed 3 x 10min in the buffer before development. 
2.4.5 Film development and membrane stripping 
The secondary Abs used in chapter 2.4.4, are covalently bound to the enzyme 
Horseradish Peroxidase (HRP). HRP react with a substrate, and the product formed 
produces chemiluminescence, which could be detected by a film or an image station. 
Materials and instruments used during film development and membrane stripping are 
listed in table 2.10. A substrate solution was made by mixing equal amounts of the 
two solutions from the SuperSignal®West Dura Extended Duration Substrate kit. The 
membrane was incubated in the Substrate solution for 2-5min before development, 
which was performed first on the computer based Kodak image station, and then on 
the more sensitive film-based AGFA CURIX 60 developer.  
If the membrane was reused for subsequent incubation with a different primary Ab, 
the membrane had to be stripped removing the previous Abs. The membrane was 
washed with a buffer to remove excess of substrate and incubated in 1M Glycine pH 
2.2 for 30min removing the Abs, followed by neutralization for 10min in the buffer 
suitable for the next Ab. Then, the membrane was blocked in a milk solution and 
incubated with a subsequent primary Ab followed by the secondary Ab as explained 
in chapter 2.4.4. 
Table 2.10: Materials and instruments used to develop a film from a membrane, and strip a 
membrane, during western analysis.  
Material/instrument: Company: Cat#: 
Glycine 1M,  pH 2.2 Merck, Germany 04201 
SuperSignal®West Dura Extended Duration Substrate Thermo Scientific 34076 
AGFA CURIX 60 developer AGFA  
Kodak image station 2000R Kodak  
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2.5 Quantitative Polymerase Chain Reaction – qPCR 
Quantitative PCR, also called real time PCR, is a method used to amplify and 
simultaneously quantify a target DNA sequence in a given sample. This method is 
often used to quantify the mRNA level in cells. First, purified RNA is transcribed into 
complementary DNA (cDNA), which is further amplified by PCR. This enables 
quantification of a target mRNA level (i.e. gene expression). In this work, real time 
PCR was performed by employing a sequence-specific fluorogenic (TaqMan) probe 
resulting in an increase of fluorescence intensity proportional to the amount of an 
accumulating PCR product matching the probe. Materials and instruments generally 
used in qPCR are listed in table 2.11. 




2.5.1 RNA isolation and purification of RNA samples 
To isolate cellular RNA, the cell must be lysed, and the cell lysate must be purified. 
Materials, instruments and software used for RNA isolation and RNA sample 
purification are listed in table 2.12. RNA was isolated from cell pellets (harvested as 
in chapter 2.2) by using the column based RNA isolation kit from Sigma. RNA 
concentrations, the 260/280 ratio and the 260/230 ratio were measured by the 
Nanodrop 1000 instrument and recorded by the ND-1000 program, as shown in FIG. 
2.5.  
Material/instruments: Company: Cat#: 
iCycler PCR machine BIO-RAD laboratories 170-8703 
Nuclease free water BIO-RAD laboratories 10623 
PCR plates, 96 well for iCyclerIQ
TM




FIG. 2.5: RNA absorption curve. This sample had a high RNA concentration = 440,7ng/µl, 
and the 260/280 and 260/230 ratios are satisfactory.  
If 260/280 (describing the RNA/protein relation) and 260/230 (describing the RNA/ 
organic contaminant relation) ratios were lower than 2.0 and 1.7, respectively, 
ethanol precipitation was performed to purify the RNA sample as follows: 3M NaAc 
pH 5.2 was added to the RNA sample at the volume ratio of 0.1:1 and mixed well 
before the addition of 2.5 volumes of absolute ethanol. The sample was mixed well, 
kept on ice for at least 10min, and centrifuged for 20min at 4°C at 12000g. The pellet 
was washed with 100µl 70% ethanol and centrifuged as before. Supernatant was 
discarded, while the RNA pellet was dried on ice for about 5min. 50µl RNA Storage 
buffer was added to the RNA pellet and the RNA concentration was measured by the 
Nanodrop 1000 instrument. RNA solutions with a satisfactory quality (i.e. 260/280 
and 260/230 ratios) were diluted to a concentration of 200ng/µl with a RNA storage 
buffer and stored at -80
o
C. 
Table 2.12: Materials, instruments and software used for RNA isolation and RNA sample 
purification. 
Materials/instruments/Software: Company: Cat#: 
Ethanol/ Absolutt Alkohol Prima Arcus  
GenElute
TM
 mammalian total RNA miniprep kit Sigma Aldrich, Switzerland RTN350  
Nanodrop 1000 Thermo Scientific  
ND-1000 program, Version 3.5.2 Nanodrop  
RNA storage buffer Ambion AM7001 
Sodium Acetate 3M (NaAc) pH 5.2 Novagen 69718 
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2.5.2 From RNA to complementary DNA: cDNA synthesis 
To synthesize cDNA from RNA, 5µl of a 200ng/µl RNA sample was mixed with 
10µl nuclease free water, 4µl 5x iScriptTM reaction mix and 1µl Reverse 
transcriptase iScript TM to give a total volume of 20µl (materials listed in table 
2.13.). The cDNA synthesis program was as follows: 22°C for 5min, 42°C for 30min, 
85°C for 5min and 4°C as a hold temperature. Then, 80µl nuclease free water was 
added to each cDNA sample, which was stored at -80°C.  




2.5.3 Real time PCR 
To quantify the expression of the selected gene, real time PCR was preformed using 
TaqMan probes. Materials, instruments and software used in real time PCR are listed 
in table 2.14. The reaction mixture for each well was as follows: 7.25µl nuclease free 
water, 1.25µl TaqMan primer/probe targeting the desired gene and 12.5µl TaqMan 
Master Mix were mixed. The mix was transferred to a 96-well PCR plate, before 4µl 
of cDNA template was added. In the negative controls, 4µl nuclease free water was 
added. The samples were run 40 cycles for 15s at 95°C and 1min at 60°C, after 5min 
initial denaturation at 95°C. The iCYCLER IQ program was used to record the data. 
Relative quantification of gene expression was performed by the Genex software in 
Microsoft excel using the ΔΔCt method, where Ct (threshold cycle) is defined as the 
cycle number at which the samples fluorescence passes the threshold value
79
. 
Relative quantification enables comparison of a level of a target mRNA (i.e. 
expression of a target gene) in a test sample relative to another reference sample. 
First, the Ct values of all samples are normalized to an endogenous housekeeping 
Material: Company: Cat#: 
5x iScriptTM reaction mix BIO-RAD laboratories 10651 
Reverse transcriptase iScript TM RT BIO-RAD laboratories 10650 
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gene, here TBP and/or RPLPO, which gives the samples ΔCt-values. Then, the 
difference between ΔCt (test sample) and ΔCt (reference (here by Melmet 79 
monolayer)), gives the ΔΔCt-values for each test sample. Relative Quantification 
(RQ), was calculated as RQ = 2
-ΔΔCt
. 
Table 2.14: Materials, instruments and software used in real time PCR. 
2.6 Complexation and transfection of siRNA 
To introduce foreign nucleic acids in mammalian cells by transient transfection, 
cationic lipid based transfection agents, such as Lipofectamine 2000 (LP2000) and 
Lipofectamine RNAi MAX (LPMAX), could be used. Lipids in complex with siRNA 
will theoretically be taken up by endocytosis, follow the endocytic pathway, and 
result in siRNA release into the cytosol. Materials used in complexation and 
transfection of siRNA are listed in table 2.15. Which type of siRNA used, varied in 
different assays, but final concentration of siRNA was always 25nM. Information 
about the siRNAs is listed in the different assay used.  
Transfection solution with LP2000 was made as follows (see FIG. 2.6 for 
illustration): 250µl RPMI without FCS (RPMI+) was mixed with 2.5µl LP2000 and 
Materials/Instruments/Software: Company: Cat#: 
Bruce Primer/Probe Applied Biosystems HS00212288 
cIAP-1 Primer/Probe Applied Biosystems HS00357350 
cIAP-2 Primer/Probe Applied Biosystems HS00154109 
Genex software v1.10 ©2004 BIO-RAD laboratories  
iCYCLER IQ
TM
, version 3.1 BIO-RAD  
Large Ribosomal protein -RPLPO Primer/Probe Applied Biosystems 4333761-0701012 
Livin Primer/Probe Applied Biosystems HS00223384 
NAIP Primer/Probe Applied Biosystems HS00244967 
Survivin Primer/Probe Applied Biosystems HS00153353 
TaqMan®Gene Expression Master Mix Applied Biosystems 4369016 
TATA Binding Protein - TBP Primer/Probe Applied Biosystems 4333769-0704010 
XIAP Primer/Probe Applied Biosystems HS00236913 
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incubated for 5min (volume of LP2000 could vary between experiments). Then the 
LP2000-solution was carefully dripped into 250µl RPMI+ mixed with 2.5µl siRNA, 
and incubated for 20min to form siRNA/LP2000 complexes. The 500µl transfection 
solution was added gently into well containing cells in 500µl fresh media (RPMI++ 
in monolayer and hESCM4 in spheroids). Incubation time varied between 
experiments 
 
FIG. 2.6: General preparation of siRNA complexes for transfection of cells. (See text for 
explanation). 
Transfection solution with LPMAX was made as follows (see FIG. 2.6 for 
illustration): 2.5µl LPMAX was mixed with 100µl RPMI+ and incubated for 5min 
(LPMAX volumes could vary between experiments). An siRNA solution containing 
100µl RPMI+ mixed with 3µl siRNA, were made, and the LPMAX solution was 
added. After 20min, 200µl transfection solution was added gently into well 
containing cells in 1000µl fresh media ( RPMI++ or hESCM4). Incubation time 
varied between experiments.   
Table 2.15: Materials used in complexation and transfection of siRNA. 
Materials: Company: Cat#: 
Lipofectamine
TM 
2000, 1µg/ml Invitrogen, CA P/N 52887 
Lipofectamine
TM
 RNAiMAX Invitrogen, CA 13778-075 
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2.7 Flow cytometry  
Flow cytometry is a method, which allows multi parameter analysis of the physical 
and/or chemical parameters of single cells. It enables identification of cell 
populations with certain qualities, based upon the specific light scattering and 
fluorescent characteristics of the individual cells. Materials, instruments and software 
generally used in Flow cytometry are listed in table 2.16. Forward scatter (FSC) 
reflects the cell size, while side scatter (SSC) reflects the complexity/granularity of a 
cell. Here, FCS and SSC parameters have been used to select, (i.e. to gate), a main 
cell population
80
 (FIG. 2.7 A). Single cells have been discriminated from duplets by 
gating on SSC width against SSC area (FIG. 2.7 B). Propidium Iodide (PI) is able to 
penetrate the cell membrane of dead/dying cells, but is not taken up by healthy cells. 
Thus, PI-staining can be used to exclude dead cells from the analysis. Prior to 
analysis, PI was added (1 g/ml, final concentration) and the gate was set to only 
include the viable cells (FIG. 2.7 C).  
 
FIG. 2.7: Representative dot plots from the flow cytometry analysis. Samples were analyzed 
by sequential gating including: main population (P1) in (A), single cells (P2) in (B) and 
living cells (P3) in (C).  
The cells from the P3 gate, i.e. viable single cells, were further analyzed for the 
fluorescence signals. The fluorescent dyes like FAM, Alexa 488 and FITC were 
identified after excitation with a blue argo n laser (488 nm), while Alexa 647 was 
identified after excitation with a red diode laser (635 nm). The cells 
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containing/binding a fluorescent dye were identified by comparing the fluorescent 
signals in the test samples versus the unstained control samples in dot plots (FIG. 2.8 
A) or in histograms (FIG. 2.8 B).  
 
FIG. 2.8: (A) A representative dot plot indicting cells positive for the fluorescent molecule 
FAM, shown in the P4 gate. The P4 gate was set adjacent to the control (i.e. cells without a 
fluorescent dye). (B) A representative histogram indicating a clear shift of the FITC-dye 
signal in the fluorescent test sample, in green, as compared to the unstained control sample, 
in red.  
Between 10000 and 20000 events were recorded for each sample. BD FACSDiva
TM 
software was used to control flow cytometer settings and sample analysis, and 
FlowJo Software was used to process the data.  
Table 2.16: Materials, instruments and software generally used in Flow cytometry. 
Materials/instruments/Software: Company: Cat#: 
BD FACSDiva
TM 
software, version 5.0.3 Becton Dickinson (BD)  
Flow cytometer - BD LSRII Becton Dickinson (BD)  
Flow tubes BD Falcon 352235 
FlowJo 7.2.5 software Tree Star Inc, Oregon  
Propidium iodide (PI) Sigma Aldrich, Switzerland 70335 
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2.8 Uptake of siRNA-FAM by microscopy and Flow 
cytometry  
To test whether Melmet cells grown as monolayer or spheroids could be efficiently 
transfected with siRNA in complex with the transfection agent LP2000, we employed 
fluorescently labeled siRNA, which could be detected by Flow cytometry using a 
488nm excitation laser or by microscopy using an Hg-lamp and a 488nm filter. 
(siRNA sequence: 1.strand: 6-FAM(carboxyfluorescein)-5`-AUU-CUU-CCC-CUC-
UCU-ACA-AdTdT-3`, 2.strand: 5`-UUG-UAG-AGA-GGG-GAA-GAA-GAA-
UdTdT-3`). Unlabeled siRNA was used as a negative control. Materials, instruments 
and software used to study uptake of siRNA-FAM were listed in table 2.17.   
Approximately 2.0x10
5
 monolayer cells were seeded into a well of a 6-well plate on 
day one, transfected with siRNA complexes on day two and analyzed on day three. 
Spheroids transferred into a well of a 12-well plate were transfected with siRNA 
complexes on day one and measured on day two. One well of a 6-well plate contained 
1000µl, and one well of a 12-well plate contained 500µl of transfection solution. 
LP2000 concentration was 2.5µl/1000µl media, and the transfection solutions were 
made as described in chapter 2.6. The plate was covered in aluminum foil for light 
protection.  
Spheroids were treated similarly to monolayer cultures, but with transfection 
solutions in half the amounts.  
2.8.1 Detection by microscopy 
Monolayer cultures: On day three, the transfection media was removed, the cells were 
washed once with PBS and 1ml RPMI++, before pictures were taken by microscopy. 
Cell pictures were taken by using the AxioVision software. Fluorescence pictures 
were taken by using a FITC filter and merged with a phase contrast pictures by using 
Adobe Photoshop software. 
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Spheroids: On day two, spheroids were disintegrated as described above and the 
single cell solution was transferred to a new well in a 12-well plate. The cells were 
allowed to attach for 3-4 hours before the picture were taken and processed as 
described above. 
2.8.2 Detection by Flow cytometry 
Monolayer cultures: On day three, the transfection media was discarded, the cells 
were washed once with PBS and incubated with Trypsin. 4ml RPMI++ was added to 
inhibit Trypsin, and the cell suspension was centrifuged for 5min at 1200rpm. Pellet 
was washed once with RPMI++ and centrifuge d for 5min at 1200rpm. The cell pellet 
was resuspended in 500µl RPMI++, filtered trough a flow-tube filter and collected in 
a flow tube. The samples were kept on ice in the dark until analysis by the flow 
cytometer as described in chapter 2.7.  
Spheroids: On day two, the spheroids were sedimented in media once, and in PBS 
twice, to separate big spheroids from the single cells and small cell clumps, which 
stayed in the solution and could be discarded. Then the pellet of the big spheroids was 
treated with 100µl Trypsin until the spheroids were dissembled into single cells. 
RPMI++ was added and the cell suspension was centrifuged for 5min at 1200rpm. 
The pellet was washed with RPMI++, centrifuged again, resuspended in 500µl 
RPMI++ and transferred into a flow tube and analyzed by the flow cytometer as 









Table 2.17: Materials, instruments and software used by Flow cytometry and microscopy, 
investigating uptake of siRNA-FAM. 
Materials/Instruments/Software: Company: Cat#: 
Adobe Photoshop CS2, software   
Aluminum foil   
AxioVision Rel 4.6, software   
Lipofectamine
TM 
2000, 1µg/ml Invitrogen, CA P/N 52887 
Microscope Axiovert 200M Zeiss  
siRNA  Silencer® Negative Control Ambion AM4611 
siRNA-FAM 20µM OliGold  
Trypsin EDTA BioWittaker
®
, Belgium 17-161E 
 
2.9  Detection of DR4 and DR5 level  by Flow cytometry 
The levels of DR4 and DR5 were determined by flow cytometry in Melmet cells 
grown as monolayers or as spheroids. Materials used when detecting DR4 and DR5 
levels are listed in table 2.18. Since the primary DR5-specific Ab did not have a 
fluorescent label, the use of a secondary Ab labeled with a fluorescent dye was 
necessary. Therefore DR5 primary Abs were used in combination with Alexa 488- or 
Alexa 647-labeled secondary Abs that could be detected by the flow cytometer 
following excitation with a blue or a red laser, respectively. Samples treated with the 
mouse IgG1, which should not bind any specific surface molecule, was used as a 
control and to set the gates to identify DR5 positive cells. DR4 primary Ab was 
labeled with Alexa 488 and, therefore, did not require a secondary Ab. Mouse IgG1 
FITC was used as an isotype control. Various concentrations of DR5 and DR4 Abs 
were tested to stain ~350x10
3
 cells. HeLa and HCT116 cells were used as positive 
controls, as recommended by the manufactures (data not shown).  
Monolayer cells were EDTA treated and diluted with RPMI++. Spheroids were 
sedimented, washed in PBS, sedimented again, treated with EDTA to disintegrate the 
spheroids and diluted in RPMI++. Cells were counted to determine cell concentration 
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in the suspension.  The cell suspension was centrifuged for 8min at 1500rpm and 
pellet was washed in PBS with 2% FCS, before centrifugation for 8min at 1500rpm. 
The cell pellet was resuspended in Flow blocking buffer (Fbb) until the final 
concentration of ~350x10
3
 cells in 50µl buffer. 50µl cell suspension was transferred 
into each test tube containing 50µl Fbb with the desired concentration of primary Ab 
and mixed gently. After incubation for 30min on ice, 900µl PBS with 2% FCS were 
added, and the tubes were centrifuged for 8min at 1500rpm. Samples stained with the 
fluorescently labeled anti-DR4 were resuspended in 500µl PBS with 2% FCS and 
pipetted through a filter into a flow tube. The tubes were kept on ice in the dark 
before analysis. Samples stained with the unlabeled anti-DR5 had to be incubated 
with the fluorescently labeled secondary Ab. Therefore, the cell pellet was 
resuspended in 1ml PBS with 2% FCS, centrifuged for 8min at 1500rpm and the cell 
pellet was mixed with 100µl Fbb containing secondary Ab at the concentration of 
4µg/100µl. After incubation for 30min on ice, 900µl PBS with 2% FCS were added, 
the tubes were centrifuged for 8min at 1500rpm, and the cell pellet was resuspended 
in 500µl PBS with 2% FCS. Cell suspension was pipetted through a filter into a flow 
tube, and the tubes were kept on ice in the dark before Flow cytometry analysis as 
described in chapter 2.7.  
Table 2.18: Materials used when detected DR4 and DR5 level by Flow cytometry. 
Material: Company: Cat#: 
Alexa Fluor® 488, goat anti-mouse-IgG1 Invitrogen, USA A21121 
Alexa Fluor® 647, goat anti-mouse-IgG1 Invitrogen, USA A21240 
Aluminum foil   
Gammagard S/D N.V Baxter S.A, Belgium  
HCT116 colorectal adenocarcinoma cell line ATCC (Manassas, VA)  CCL-247 
HeLa cell line ATCC (Manassas, VA) CCL-2 
IgG1 antibody Sigma Aldrich, Switzerland I5381 
Monoclonal Ab to DR5, mouse anti-human eBioscience 14-9908 
Mouse anti-human CD 261/DR4 Alexa 488 Serotec MCA2332A488 





2.10 Evaluation of cell viability following treatment with 
TRAIL receptor antibodies 
Melmet cultures grown as monolayer were tested for survival after treatment with the 
TRAIL receptor Abs: HGS-ETR 1 and HGS-ETR 2 by MTS assay. MTS is reduced 
into formazan in metabolically active (i.e. viable) cells. The production of formazan 
(soluble, colored molecule) is proportional to the number of living cells, and thus the 
produced color is an indication of the viability of cells. Materials and instruments 
used when evaluating cell viability after treatment with TRAIL receptor Abs are 
listed in table 2.19. Untreated cells and cells treated with HGS-IgG were used as 
controls. Melmet 1 and 5 cells were seeded at densities 3000 cells per well, and 
Melmet 79 – at density 4000 cells per well, in a 96 well plate on day one. On day 
two, Ab solutions (at the final concentrations 1µg/ml and 10µg/ml) were added to the 
cells.  
On day five, 20µl MTS (Cell Titer 96®Aqueous Cell Proliferation Assay) was added 
to each well, and plates were incubated for 2-3hours at 37°C. Absorption was 
measured at 490nm for 1second by the Wallac instrument, and used to calculate cell 
viability.   
Table 2.19: Materials and instruments used when evaluating cell viability after treatment 
with TRAIL receptor antibodies. 
Materials/Instruments: Company: Cat#: 
Cell Titer 96®Aqueous Cell Proliferation Assay (MTS) Promega (Madison, WI) G3581 
HGS-IgG  Human Genome Sciences Not available  
HGS-ETR 1 Human Genome Sciences Not available 
HGS-ETR 2 Human Genome Sciences Not available  
Victor2 Wallac 1420 multi label counter  Wallac MR1463 
2.11 Spheroid forming assay 
A spheroid forming assay, is an assay where cells are tested for the ability to form a 
new passage of non-adherent spheroids from a single cell i.e. its spheroid forming 
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capacity (SFC). In many cancer types, including melanoma, SFC seems to reflect 
tumor initiating capacities of the cells in vivo
19
. Materials and instruments used in 
spheroid forming assay are listed in table 2.20. Melmet cells were tested for their SFC 
when grown in hESCM4 containing HGS-ETR 1 and HGS-ETR 2. Untreated cells 
and cells treated with HGS-IgG were used as controls. Single cells from disintegrated 
spheroids were seeded out at low density, i.e. 1000 cells per 5cm dishes in 4ml 
hESCM4 containing 10µg/ml HGS-ETR 1 or HGS-ETR 2. Every other day 1ml fresh 
media was added to the dishes. When “big” spheroids were formed in the control 
dishes, all samples were evaluated, and spheroids larger than 110µm were counted 
using a Nikon microscope. A certain inaccuracy was expected, since non-
computerized counting will be influenced by a manually variation. Relative sphere 
formation (RSF) relative to untreated control was calculated from the obtained data. 
Table 2.20: Materials and instrument used in spheroid forming assay. 
Material/Instrument: Company: Cat#: 
HGS-ETR 1 Human Genome Sciences Not available  
HGS-ETR 2 Human Genome Sciences Not available  
HGS-IgG Human Genome Sciences Not available  
Microscope Nikon, Japan  
 
2.12 Evaluating transfection efficiency and toxicity with 
siRNA complexed to Lipofectamine 2000 or 
Lipofectamine RNAi MAX. 
Different cell lines show different transfection efficiency and toxicity when exposed 
to different transfection agents. Materials and instruments used when evaluating these 
two parameters, when transfecting cells with siRNA in complex with lipid based 
transfection agents, are listed in table 2.21. Complexation and transfection were 
preformed as described in chapter 2.6. Melmet cells grown as monolayer were tested 
for down-regulation of the protein XIAP after treatment with anti-XIAP siRNA in 
complex with LP2000 or LPMAX.  
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When testing down regulation, 2.0x10
5
 cells of Melmet 1 and 5, and 3.0x10
5
 cells of 
Melmet 79 were seeded out in a well of a 6-well plate on day one. The cells were 
transfected on day two. LP2000 volume of 2.5µl and 5µl/1000µl end volume, and 
LPMAX volume of 2.5µl and 7µl/1200µl end volume were tested. Cells were 
harvested for western blot analysis on day four (as described in chapter 2.2). Protein 
lysate was made and analyzed by SDS-PAGE and western blotting (as explained in 
chapter 2.4). The efficiency of XIAP down-regulation was evaluated comparing the 
XIAP level in treated samples with XIAP level in untreated control cells.   
When testing toxicity, 3000 cells of Melmet 1 and 5 and 4000 cells of Melmet 79 
were seeded in a well in a 96-well plate on day one. The cells were transfected on day 
two with negative control siRNA in complex with a LP2000 at a concentration of 5µl 
per 1000µl media, or a LPMAX concentration of 2.5µl, 7.5µl or 12.5µl LPMAX per 
1200µl media. Untreated cells were used as control. MTS assay were preformed on 
day three, and cell viability relative to control cells, were calculated (as in chapter 
2.10). Toxicity was also tested after three days of incubation, i.e. MTS assay on day 
five, with LP2000 (5µl/1000µl media).   
Table 2.21: Materials and instrument used when evaluating toxicity and transfection 
efficiency of LP2000 and LPMAX in complex with siRNA.  
Material/Instrument: Company: Cat#: 
Anti-XIAP siRNA  Ambion AM16708 (ID 121292) 







2000, 1µg/ml Invitrogen, CA P/N 52887 
Lipofectamine
TM
 RNAiMAX Invitrogen, CA 13778-075 
siRNA  Silencer® Negative Control Ambion AM4611 




2.13 Combinatorial effects – TRAIL receptor antibodies 
and siRNA 
Melmet cells grown as monolayer were tested for survival, and cells grown as 
spheroids were tested for their SFC, after combined treatment with HGS-Abs and 
siRNA against XIAP or survivin. The type and the amount of transfection agent used 
to make complexes with siRNA, was determined by optimization as described in 
chapter 2.12 and chosen for each Melmet. Materials and instruments used when 
testing combinatorial effects are listed in table 2.22. 
Cells grown as monolayer were seeded at a density 3000 cells per well in a 96-well 
plate on day one. (See FIG. 2.9. for illustration.) On day two, the cells were 
transfected with siRNA as described in chapter 2.6. On day three, 10µg/ml HGS-ETR 
1 or HGS-ETR 2 were added together with new RPMI ++. Cell viability was 
measured by the MTS assay on day five (as in chapter 2.10). 
FIG. 2.9: Time based overview of combinatorial treatment of monolayer and spheroids. 
On day one, single cells from disintegrated spheroids were seeded at a density 700 
cells per well in a 24-well non-adherent plate and transfected as described in chapter 
2.6 (see FIG. 2.9. for illustration.), except Melmet 79, which were transfected in half 
the LP2000 concentration used when transfecting monolayer cells. On day two, the 
cell and the media were transferred to a 6-well plate, and treated with 10µg/ml HGS-
ETR 1 or HGS-ETR 2. 0.5ml hESCM4 was added to the wells every other day until 
large spheroids were formed in the control well. Spheroids larger than 110µm were 
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counted manually using a Nikon microscope, and RSF was calculated. Pictures were 
taken using the GelCount machine. 
Table 2.22: Materials and instruments used in combinatorial treatment with TRAIL-like 
antibodies and siRNA.   
Materials/Instruments: Company: Cat #: 
24 well non adherent plate Costar®, USA 3473 
Anti-survivin siRNA  Ambion AM 16708 (ID 121295) 
Anti-XIAP siRNA  Ambion AM16708 (ID 121292) 
GelCounter Oxford Optronix  
HGS-ETR 1 Human Genome Sciences Not available  
HGS-ETR 2 Human Genome Sciences Not available  
HGS-IgG Human Genome Sciences Not available  
Lipofectamine
TM 
2000, 1µg/ml Invitrogen, CA P/N 52887 
Lipofectamine
TM
 RNAiMAX Invitrogen, CA 13778-075 
Microscope Nikon, Japan  




3.1 Expression of IAPs in metastatic melanoma cell 
cultures: monolayers versus spheroids 
Cancer cells tend to have a higher apoptotic resistance compared to healthy somatic 
cells. One of the reasons for the reduced apoptotic ability could be related to an 
elevated level of anti-apoptotic proteins, for instance the IAPs. In this study the 
expression of IAPs in Melmet 1, 5 and 79 was evaluated. The level of seven different 
IAPs (survivin, XIAP, livin, cIAP-1, cIAP-2, Bruce and NAIP) was evaluated by 
western blot and/or real time PCR. Cells grown as spheroids and cells grown as 
monolayers were compared with respect to the levels of IAPs, in order to evaluate if 
growth conditions influence the IAP expression. To investigate whether melanoma 
cells, which survive under in vivo conditions and manage to seed a tumor, could have 
enhanced anti-apoptotic properties, the expression level of IAPs in melanoma cells 
from in vivo was also evaluated. For this purpose, melanoma cells isolated from 
experimental metastases established in rat tibia following systemic injection of 
Melmet 1 or Melmet 5 cells were analyzed.  
Protein levels often reflect a cells status better than mRNA levels. Therefore, the 
western blot data were considered more reliable than the real time PCR data when 
conclusions were made about the expression of IAPs in various Melmet cultures. In 




FIG. 3.1: Representative western blots describing (A) survivin, (B)  XIAP, (C) livin (α 39kD, 
β 37kD), (D) cIAP-1 and (E) cIAP-2 protein levels in Melmet 1, 5 and 79 grown as 
monolayer (mono) or as spheroids (sph). “Tibia” denotes in vivo samples i.e. Melmet 1 and 
Melmet 5 cells isolated from experimental metastases in rat tibia. α-tubulin was used as a 
loading control. All IAPs were tested on two biologically independent sets of samples by 
western blot analysis.  
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Survivin was clearly expressed in all samples, as shown by western blot (FIG. 3.1 A) 
and confirmed by real time PCR (data not shown). Both Melmet 1 and 79 showed an 
elevated survivin level in the spheroids compared to the corresponding monolayers 
(FIG. 3.1 A), and this elevated expression was verified by quantification of band 
intensity (data not shown). However, growth condition had no influence on survivin 
expression in Melmet 5. Also melanoma samples from in vivo, i.e. experimental 
metastases in rat tibia, showed no deviation from in vitro cultures with respect to the 
levels of survivin. . 
All three Melmet cell lines expressed XIAP, according to both western blot (FIG. 3.1 
B) and real time PCR analysis (data not shown). The XIAP level in Melmet 1 and 5 
was independent on growth environment both when analysed by western blot and real 
time PCR. Both methods pointed, however, towards a higher XIAP expression in the 
spheroids compared to the monolayer in Melmet 79. 
Melmet 1 and Melmet 5 monolayers did not express livin, according to western blots 
(FIG. 3.1 C) and real time PCR (data not shown). However, livin was detectable in 
Melmet 5 spheroids, and even higher levels of livin was observed in the Melmet 5 
samples from tibia (i.e. experimental metastases originating from injected Melmet 5 
spheroid cells), as revealed both by western blots and real time PCR. Also, in Melmet 
79 an elevated level of livin in the spheroids compared to the monolayer, was 
detected by both methods.  
All Melmet 1 and Melmet 5 originating samples had similar amounts of cIAP-1, 
according to western blots (FIG. 3.1 D) and real time PCR (data not shown). Melmet 
79 contained, according to western blot, a higher cIAP-1 level in the spheroids 
compared to the monolayer, but the real time PCR data pointed towards a similar 
level. A distortion of the cIAP-1 band in the tibia sample from Melmet 1 was 
probably due to a large amount of an unknown protein seen at ~70kD in the in vivo 
samples (detected by amidoblack staining, data not shown). 
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cIAP-2 levels in Melmet 5 were considered equal, based on both western blot (FIG. 
3.1 E) and real time PCR analysis (data not shown). Melmet 1 and 79 spheroids 
showed a slightly elevated expression of cIAP-2 compared to the monolayer 
according to western blots (verified by quantification of intensity, not shown), which, 
however, was not confirmed by real time PCR data in respect to Melmet 1. The in 
vivo samples from tibia showed no increase in the cIAP-2 levels compared to the 
corresponding in vitro samples. 
 
FIG. 3.2: Relative quantification based on real time PCR data for the expression of (A) 
Bruce and (B) NAIP in Melmet 1, 5 and 79 grown as monolayer and as spheroids. Changes 
in Bruce and NAIP expression relative to the expression in Melmet 79 monolayer and 
Melmet 79 spheroids, respectively, are presented. Error bars indicate standard deviations 
from two parallels in one experiment. 
Western blotting was also preformed attempting to evaluate the expression of Bruce 
and NAIP, but, due to technical problems related to antibodies, no conclusions could 
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be drawn. Therefore, the real time PCR data constituted a basis when looking at 
trends of Bruce and NAIP expression in various Melmet cultures.  
As shown in FIG. 3.2 A, Bruce was expressed in all samples. Melmet 1 monolayer 
had an increased Bruce level compared to the spheroids, whereas Melmet 5 tended in 
the opposite direction. Similar levels of Bruce were observed in both Melmet 79 
cultures. 
NAIP was not detectable in Melmet 1 or 5 (FIG. 3.2 B). Only Melmet 79 spheroids, 
but not the monolayer cells, had detectable level of NAIP.  
 
FIG. 3.3: Relative IAP levels in monolayer (mono) and spheroids (sph) of Melmet 1 (M1), 
Melmet 5 (M5) and Melmet 79 (M79) based on observations from western blot. The highest 
detected level within a group of a specific IAP was denoted as “XXX”, and the other 
samples were scored related to this sample: “XXX” (strong expression, “XX” (medium 
expression), “X” (low expression) and “-“(not expressed), and are not to be compared 
between different IAPs. Purple boxes indicate an elevated IAP level in spheroids as 
compared to the respective monolayers. Quantification of band intensity for verification, are 
indicated by an “*”. 
In summary, all IAPs, except livin and NAIP, were expressed in all Melmet cultures 
studied. When comparing IAP levels in monolayers versus spheroids (FIG. 3.3), 8 of 
15 (~53%) cases studied indicated an increased IAP level in the spheroids. The rest of 
the cases showed no differences in expression between the spheroids and the 
respective monolayer cultures.  
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3.2 Expression of death receptors DR4 and DR5 in 
melanoma cells cultured as monolayers or spheroids 
TRAIL initiates the extrinsic apoptotic pathway via activation of the surface receptors 
DR4 and DR5. The levels of DR4 and DR5 in Melmet 1, 5 and 79 grown as 
monolayers and as spheroids were evaluated by staining the cells with anti-DR4/DR5 
Abs followed by flow cytometric analysis.  
To define an optimal DR4 and DR5 Ab-concentration, the Abs were titrated. The 
overlapping histograms (as illustrated in FIG. 3.4) indicate that receptor saturation 
was achieved both for the DR4 and DR5 Ab, and this was observed in all Melmet 
cultures. As shown in FIG. 3.4, 20µg of DR4 Ab and 2µg of DR5 Ab per 100µl cell 
suspension was sufficient for receptor saturation, and these Ab concentrations were 
used in the subsequent receptor analysis (presented in FIG. 3.5 and FIG. 3.6).  
FIG. 3.4: Titration of DR4 and DR5 antibodies to verify receptor saturation. (A) 
Representative histograms indicating the DR4 antibody titration, here for Melmet 79 
spheroids, with 2µg, 10µg and 20µg of the antibody per 100µl cell suspension. (B) 
Representative histograms indicating the DR5 antibody titration, here for Melmet 5 
monolayer, with 0.1µg, 0.5µg and 2.0µg of the antibody per 100µl cell suspension. Amount 




FIG. 3.5: Flow cytometry-based histograms indicating (A) DR4, and (B) DR5 Ab-stained 
cell populations in Melmet 1, Melmet 5 and Melmet 79 monolayer and spheroids. Amount of 




FIG. 3.6 (A) DR4 and (B) DR5 levels presented as relative median increase (i.e. 
fluorescence median in the test sample relative to fluorescence median in the control sample 
based on Flow cytometry measurements) in Melmet 1, 5 and 79 cells grown as monolayer 
and as spheroids.  
DR4 positive cells were identified in all Melmet cultures (FIG. 3.5 A), though a 
relatively weak staining was observed, i.e. only a partial shift of the stained cell 
population versus the control cells, could be seen, leading to the conclusion that the 
Melmet cells have a relatively low amount of DR4. Spheroids tended to have a 
slightly higher level of DR4 than the corresponding monolayers in all Melmets, as 
shown in FIG. 3.6 A.  
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All Melmet cell lines were strongly stained with the DR5 antibody (FIG. 3.5 B), 
suggesting that Melmet cells have a high level of DR5 receptors. As for DR4, Melmet 
1 and 5 also had a higher DR5 level in the spheroids as compared to the respective 
monolayers (FIG. 3.6 B). 
Generally, there was not a separate unique cell population with very high or low 
levels of DR4 or DR5, suggesting that the majority of the cells in the Melmet cultures 
studied have somewhat similar levels of DR4 or DR5. 
3.3 Sensitivity of melanoma cell cultures to the treatment 
with TRAIL receptor antibodies 
Since the Melmet cell lines were concluded to express DR4 and DR5, TRAIL 
receptor Abs from HGS were employed to activate the apoptotic pathway via the 
death receptors. As mentioned previously, HGS-ETR 1 targets DR4 while HGS-ETR 
2 binds DR5. An HGS-IgG Ab not targeting any specific receptor was used as a 
negative control. Melmet 1, 5 and 79 grown as monolayers were treated with Ab at 
concentrations of 1µg/ml and 10µg/ml for 48h and the cell viability was measured by 
using the MTS assay.  
As shown in FIG. 3.7, all Melmets demonstrated a dose-dependent response to the 
TRAIL receptor Abs. At the highest Ab concentration used i.e. 10µg/ml, Melmet 1 
demonstrated a cell viability of ~ 90% and ~70% when treated with HGS-ETR 1 and 
HGS-ETR 2, respectively (FIG. 3.7 A). Melmet 5 responded primarily to HGS-ETR 
2 (10µg/ml), resulting in a cell viability of ~ 70% (FIG. 3.7 B). The best response to 
both HGS-ETR 1 and HGS-ETR 2, was seen in Melmet 79, where ~75% and ~40% 
viability, respectively, was observed following the treatment with 10µg/ml Abs (FIG. 
3.7 C). HGS-IgG had no noteworthy effect in all three Melmets when compared to 




FIG. 3.7: Cell viability of (A) Melmet 1, (B) Melmet 5 and (C) Melmet 79 monolayer treated 
with TRAIL receptor antibodies from HGS at concentrations 1µg/ml and 10µg/ml. Data 
presented in (A) describe average values, and standard error of the mean, based on two 
independent experiments. Data presented in (B) and (C) are based on a single experiment. 





Melmet 1, 5 and 79 spheroid-derived cells were treated with TRAIL receptor Abs at 
the concentration of 10µg/ml, to examine whether their spheroid forming capacity 
(SFC) could be affected by the treatment. Data were related to untreated control and 
presented as relative spheroid formation (RSF).    
 
FIG. 3.8: Relative spheroid formation in (A) Melmet 1, (B) Melmet 5 and (C) Melmet 79 
after treatment with TRAIL receptor antibodies. Spheroids larger than 110µm were counted, 
and data are based on one assay with two parallels with satisfactory standard deviations. 
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Generally, the effect of TRAIL receptor Abs, particularly HGS-ETR 2, was much 
more pronounced on the spheroid forming cells (FIG. 3.8) than on the monolayer 
cells (FIG. 3.7) in all Melmet lines. However, also the HGS-IgG had an effect on 
SFC (FIG. 3.8). Melmet 1 had a similar response to HGS-IgG and HGS-ETR 1, 
resulting in a ~75% RSF compared to untreated cells, and a strong response to HGS-
ETR 2, resulting in ~5% RSF (FIG. 3.8 A). The SFC of Melmet 5 (FIG. 3.8 B) and 
Melmet 79 (FIG. 3.8 C) were also affected by negative control HGS-IgG (~80% 
RSF). Still, RSF of ~70% and ~40% were observed in Melmet 5, following treatment 
with respectively HGS-ETR 1 and HGS-ETR 2. Melmet 79 treated with HGS-ETR 1 
or HGS-ETR 2 resulted in ~65%, and ~50% RSF, respectively. 
 Phase contrast microscopy pictures (FIG. 3.9) illustrate the differences seen in the 
spheroid formation following the treatment with HGS-IgG and HGS-ETR 2.   
FIG. 3.9: Representative pictures from a spheroid forming assay, here represented by 
Melmet 1, treated with HGS-IgG (negative control) and HGS-ETR 2. Pictures were taken 
eight days after initiation of experiment with a 5x objective. 
As can be seen in FIG. 3.9, spheroid forming cells treated with HGS-ETR 2 formed 




FIG. 3.10 compares DR4 or DR5 levels with their response to their respective TRAIL 
receptor Abs in Melmet 1, 5 and 79. Data plotted present percent cell viability 
relative to HGS-IgG (in blue) and DR4 or DR5 level as relative median measured by 
flow cytometry in chapter 3.2 (in green). 
No obvious trends were seen between DR4 level and response to HGS-ETR 1. On the 
other hand, DR5 tended to associate to HGS-ETR 2 response, especially in Melmet 1. 
All together this indicates that the treatment with HGS-ETR 2, which targets DR5, is 
more efficient than the treatment with HGS-ETR 1, i.e. HGS-ETR 2 induces higher 
cell death and stronger inhibition of spheroid forming capacity.  
FIG. 3.10: (A) DR4 level presented in relative median in green, right y-axis (as in FIG. 3.6) 
versus percent cell viability after treatment with HGS-ETR 1 in blue, left y-axis (as in FIG. 
3.7 and FIG. 3.8). (B) DR5 level presented in the same way as in (A), after treatment with 
HGS-ETR 2.  
3.4 Uptake of siRNA complexes into melanoma cells 
cultured as monolayers or as spheroids 
Elevated IAP level could inhibit the extrinsic apoptotic pathway. The IAP level in 
cancer cells could be down-regulated by transfection with anti-IAP siRNA, in this 
way facilitating apoptosis. Since treatment with Abs from HGS did not result in death 
of the entire Melmet cell population, we wanted to combine the Ab-based treatment 
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and transfection with anti-IAP siRNA to try to enhance cell death. Knowing that 
transfection efficiency is dependent on cellular uptake of siRNA molecules, we first 
studied the uptake of fluorescently labelled siRNA into Melmet cells cultured as 
monolayers or spheroids.  FAM-labelled siRNA were complexed with Lipofecatmine 
2000, and the uptake of the complexes were studied by microscopy. As can be seen in 
FIG. 3.11, some fluorescent green spots, likely reflecting FAM-siRNA, could be 
identified in the pictures of both monolayer and spheroid cells.  
FIG. 3.11: Representative microscopy pictures of monolayer and spheroids transfected with 
siRNA-FAM, represented by Melmet 1 and Melmet 79, respectively. The pictures display an 
overlay of fluorescence pictures and phase contrast pictures. After transfection, the 
spheroids were dissociated into single cells which were allowed to attach to a well bottom 
before the pictures were taken. 
However, due to fast bleaching of the FAM dye and non-three-dimensional images, it 
was difficult to conclude whether the siRNA complexes localised intracellularly, and 
whether the uptake was efficient. Thus, the microscopy analysis did not give the 
required information regarding the transfection efficiency of various Melmet cultures.     
To retrieve more accurate data, flow cytometry was used to examine the Melmet cells 




FIG. 3.12: Dot-plots indicating percent of FAM-positive cells in Melmet 1, 5 and 79 grown 
as monolayer and as spheroids transfected with siRNA-FAM complexes. Forward scatter 
(FSC-A) were plotted against FAM intensity, in a logarithmic fashion. 
All Melmets grown as monolayers resulted in over 90% FAM-positive cells, 
indicating that the vast majority of the monolayer cells internalized FAM-siRNA. 
Much fewer spheroid cells were FAM-positive: 2% of Melmet 1, and about 20% of 
Melmet 5 and 79, indicating that the uptake of the FAM-siRNA complexes was much 
weaker in the spheroids as compared to the monolayer cells. 
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We hypothesized that the reason for poor spheroid transfection could be related to 
spheroid size, i.e. a transport barrier for “big” siRNA complexes. To investigate this, 
spheroids of different size were treated with FAM-siRNA complexes, separated into 
“big” and “small” spheroids based on different sedimentation rates, disintegrated into 
single cells and analyzed by flow cytometry.  
 
FIG. 3.13: Uptake of FAM-siRNA complexes into Melmet 79 cells from the spheroids of 
different size (for comparison, uptake into Melmet 79 monolayer cells is presented). Small 
and big spheroids were separated by exploiting the different sedimentation rates, 
disintegrated into single cells and analysed by flow cytometry. Forward scatter (FCS-A) was 
plotted against FAM intensity, in a logarithmic fashion.  
As shown in FIG. 3.13, the transfection efficiency of small spheroids from Melmet 79 
was notably higher compared to the bigger spheroids, however, lower than in the 
monolayer cells. Similar results have been obtained also in Melmet 1 and 5 (data not 
shown), confirming that the spheroid size is a limiting factor for the delivery of 
siRNA complexes. These observations were very important designing the protocols 
for treatments of the spheroid-derived cells: Melmet spheroid cells should always be 
in a single cell manner during the treatment, to enhance the uptake of siRNA 
complexes or other big therapeutic molecules, i.e. to maximise a possible effect.   
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3.5 Evaluation of transfection efficiancy and toxicity of the 
transfection agents Lipofectamine 2000 and 
Lipofectamine RNAi MAX 
The efficiency of LP2000 and LPMAX, two lipid-based transfection agents often 
used for delivery of siRNA, was tested in Melmet 1, 5 and 79 when grown as 
monolayer. Cells were transfected with anti-XIAP siRNA in complex with LP2000 or 
LPMAX at various lipid concentrations, and the efficiency of XIAP down-regulation 
as well as the toxicity was measured. Anti-XIAP was used, since all Melmets clearly 
expressed XIAP as detected by western blot analysis (chapter 3.1).  
 
FIG. 3.14: Down regulation of XIAP in Melmet 1, 5 and 79 transfected with anti-XIAP 
siRNA in complex with (A) LP2000, or anti-XIAP siRNA in complex with (B) LPMAX. 
Untreated control (Ctr.) was compared to cells transfected with siRNA in complex with 2.5µl 
or 5.0µl LP2000 per 1000µl final volume, or to cells transfected with siRNA in complex with 
2.5µl or 7.0µl LPMAX per 1200µl final volume (details see chapter 2.6). α-tubulin was used 
as loading control. 
Melmet 1 and 5 demonstrated the best down-regulation of XIAP using LPMAX, 
while LP2000 was the most efficient transfection agent in Melmet 79 (FIG. 3.14). A 
stronger down regulation was achieved when a higher lipid concentration was used in 
all Melmets.  
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Since transfection agents have a tendency to be toxic to some cell lines
69
, the toxicity  
of LP2000 and LPMAX were tested, by transfecting the cells with negative control 
siRNA in complex with LP2000 or LPMAX at various concentrations (FIG. 3.15). 
MTS assay were performed one day after the transfection.   
 
FIG. 3.15: Cell viability (in percent of control) of (A) Melmet 1, (B) Melmet 5 and (C) 
Melmet 79 transfected with negative control-siRNA in complex with LP2000 (5µl in 1000µl 
media) or LPMAX (2.5µl, 7.5µl or 12.5µl in 1200µl media), compared to untreated cells 
(ctr) after 24hour incubation. Standard deviations represent variations from three parallels.  
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As can be seen in FIG. 3.15, LPMAX gave no toxicity in any Melmet, independent of 
the concentrations, while LP2000 resulted in some toxicity (~20%) after one day 
incubation. When cells were incubated with LP2000-based complexes for longer 
time, i.e. three days, even higher toxicity was observed for Melmet 1 and Melmet 5 
(FIG. 3.16). 
 
FIG. 3.16: Cell viability (in percent of untreated control cells) in Melmet 1, 5 and 79 
transfected with negative control-siRNA in complex with LP2000 (5µl LP2000 in 1000µl 
media), after three days incubation. Standard deviations represent variations from three 
parallels. 
Thus, LP2000 gave only slight down-regulation of XIAP in Melmet 1 and 5 (FIG. 
3.14), and resulted in some toxicity in Melmet 1 and 5 (FIG. 3.15 A and B and FIG. 
3.16), indicating that LP2000 is not a good transfection agent for Melmet 1 and 5. 
Instead, 7.5µl LPMAX per 1200µl media was chosen when transfecting Melmet 1 
and 5. 5µl LP2000 per 1000µl media was chosen for transfection of Melmet 79, since 
LP2000 gave satisfactory down-regulation of XIAP (FIG. 3.14) and relatively low 
toxicity (FIG. 3.15 C and 3.16).  
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3.6 Sensitivity of melanoma cell cultures to the combined 
treatment with siRNA targeting IAPs and TRAIL 
receptor antibodies  
To investigate whether the combined pro-apoptotic treatment could enhance the death 
of melanoma cells, the Melmet cell lines were tested for treatment with anti-IAP 
siRNAs and TRAIL receptor Abs. Since all Melmets expressed XIAP and survivin, 
and since survivin and XIAP are among the most studied IAPs, anti-XIAP and anti-
survivin siRNA were chosen to be combined with TRAIL receptor Abs. 
3.6.1 Monolayer 
Melmet 1, 5 and 79, grown as monolayers, were tested for cell viability after 
treatment with TRAIL receptor Abs and/or transfection with anti-IAP siRNA. Abs 
from HGS were used at the concentration of 10µg/ml. 
Melmet 1 displayed no effect after treatment with HGS-IgG and HGS-ETR 1, but a 
20% reduction in cell viability was observed when treated with HGS-ETR 2 (FIG. 
3.17 A), consistent with the results in chapter 3.3. Treatment with negative control 
siRNA-LPMAX resulted in 10% toxicity, reflecting the toxicity inducible by the 
transfection agent LPMAX. No obvious effect was observed when treating the cells 
with anti-XIAP or anti-survivin alone or in combination with HGS-IgG or HGS-ETR 
1. Anti-XIAP treatment combined with HGS-ETR 2 was the only treatment strategy, 
where a down regulation of the IAP tended to contribute to a reduction of cell 
viability. The XIAP knock-down combined with HGS-ETR 2 resulted in an 
additional effect of approximately 10%, compared to cells treated with HGS-ETR 2 





FIG. 3.17: Cell viability (expressed as percent of untreated control) of (A) Melmet 1, (B) 
Melmet 5 and (C) Melmet 79 grown as monolayer, after treatment with antibodies from HGS 
and/or transfection with siRNA-lipid complexes (negative control siRNA, anti-XIAP siRNA 
or anti-survivin siRNA). Cell viability and standard errors of the mean are based on three 
independent assays for Melmet 1 and Melmet 5, and five independent assays for Melmet79, 




Melmet 5 was not notably affected by either Ab treatment or siRNA-LPMAX 
treatment (FIG. 3.17 B). 10-20% reduction in viability was associated to the 
treatment with the negative control siRNA-LPMAX, and likely was due to LPMAX-
mediated non-specific toxicity.  
Melmet 79 showed no toxicity following siRNA-LP2000 treatment, and little effect 
after anti-survivin treatment (FIG. 3.17 C). Anti-XIAP treatment reduced cell 
viability by 10-20%, when compared to controls in the different Ab groups. HGS-
ETR 1 resulted in about 80% and HGS-ETR 2 in about 55% cell viability when 
comparing to untreated control cells, which is consistent with the results in chapter 
3.3. When combining anti-XIAP and HGS-ETR 2, a small additive effect could be 
measured, resulting in 40% viable cells. 
3.6.2 Spheroids 
Spheroid cells showed some tendency for up-regulation of IAPs (FIG. 3.3). 
Therefore, it was of interest to investigate how the down-regulation of IAPs affects 
the spheroid-derived cells and the spheroid forming abilities. Melmet 1, 5 and 79 
spheroid-derived cells were tested for their SFC after treatment with Abs from HGS 
and/or transfection with anti-XIAP or anti-survivin siRNA. A concentration of 
10µg/ml was used when treating with Abs from HGS. Spheroids larger than 110µm 





FIG. 3.18: Relative spheroid formation (in percent of untreated control) of (A) Melmet 1,(B) 
Melmet 5 and (C) Melmet 79 grown as spheroids, after treatment with antibodies from HGS 
and/or transfection with siRNA-lipid complexes (negative control siRNA, anti-XIAP siRNA 
and anti-survivin siRNA). Relative spheroid formation and standard error of the mean are 
based on two independent experiments. Spheroids larger than 110µm were counted after 8-
14 days after incubation with Abs. 
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HGS-ETR 2 treatment resulted in a ~90% down-regulation on RSF on Melmet 1 
(FIG. 3.18 A), as observed in chapter 3.3. No change in RSF was seen when treating 
Melmet 1 cells with HGS-IgG or HGS-ETR 1, or with negative control siRNA. 
Treatment with anti-survivin or anti-XIAP siRNA tended to reduce the RSF in all Ab 
treatment groups (FIG. 3.18 A), i.e. 20-50% reduction in RSF was  observed. 
However due to the large HGS-ETR 2 effect, the siRNA effects in the HGS-ETR 2 
group were imprecise.  
LPMAX resulted in little or no toxicity in Melmet 5, as can be seen comparing 
untreated control cells with cells treated with negative control siRNA-LPMAX in all 
Ab treatment groups (FIG. 3.18 B). No clear conclusions could be drawn following 
the treatments with HGS-IgG or HGS-ETR 1, due to big variations in spheroid 
formation, suggesting that, probably, there was no considerable effect of the two Abs. 
Cells treated with HGS-ETR 2 alone showed a RSF of ~55%, basically corresponding 
with the data in chapter 3.3. The largest reduction in SFC was observed after the 
combined treatment with HGS-ETR 2 and anti-IAP siRNA, where the combined anti-
XIAP treatment reduced RSF by almost 80% and the combined anti-survivin 
treatment by nearly 65%.  
Even though using half the concentration of LP2000 used when treating Melmet 79 
monolayer, LP2000 induces 50% toxicity in Melmet 79 spheroids, comparing 
untreated control groups with groups treated with negative control siRNA (FIG. 3.18 
C). No clear Ab effect could be observed in the HGS-IgG or HGS-ETR 1 treatment 
group data. In this assay, HGS-ETR 2 treatment resulted in ~70% RSF in Melmet 79, 
not corresponding fully with results from chapter 3.3, which resulted in ~50% RSF. 
Anti-XIAP or anti-survivin treatment in Melmet 79, resulted in a ~25% and a ~15% 
reduction in RSF respectively, when compared to cells treated with negative control 
siRNA (FIG. 3.18 C). An exception was observed in the HGS-ETR 2 group, where 
all groups of siRNA treatment, resulted in the same RSF (~20% RSF).  
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For all Melmets, the individual effects of HGS-ETR 2 and of anti-IAP siRNA were 
confirmed visually in each specific assay, as demonstrated by Melmet 1  in FIG. 3.19 
and FIG. 3.20. Cells treated with HGS-IgG or HGS-ETR 1 showed in general similar 
SFC as control cells regarding both the number (FIG. 3.19), and the size of the 
formed spheroids (data not shown). 
 
FIG. 3.19: Overview pictures taken by the Gelcounter machine of wells containing untreated 
Melmet 1 cells, and Melmet 1 cells treated with HGS-IgG, HGS-ETR 1 and HGS-ETR 2 
respectively. Pictures demonstrate the visual effect of HGS-ETR 2 treatment, in respect of 




FIG. 3.20: Overview pictures of HGS-IgG treated Melmet 1 cells taken by the Gelcounter 
machine. Pictures of wells presented, contain non-siRNA treated cells, and cells treated with 
negative control siRNA, anti-XIAP siRNA and anti-survivin siRNA respectively. Pictures 
demonstrate the visual effect of anti-XIAP and anti-survivin treatment, in respect to number 
of spheroids formed. Spheroids are shown as white dots on a black background.  
The phase contrast microscopy pictures, shown in FIG. 3.21, illustrate the differences 
seen in the spheroid formation following treatments. As can be seen, untreated 
control cells formed many and big spheroids (FIG. 3.21 A). HGS-ETR 2-treated cells 
formed fewer and much smaller spheroids compared to the control cells (FIG. 3.21 
B). When anti-IAP treatment was combined with HGS-ETR 2 treatment, the cells 





FIG. 3.21: Representative phase contrast microscopy pictures, represented by Melmet 1, of 
(A) untreated spheroids, (B) spheroids treated with HGS-ETR 2, (C) spheroids treated with 
the combination HGS-ETR 2 and anti-survivin siRNA, and (D) spheroid treated with the 
combination HGS-ETR 2 and anti-XIAP siRNA. The pictures were taken 14 days after 
initiation of experiment with a 5x objective.  
Spheroids (and to some extent monolayers) demonstrated a various response to HGS-
IgG. The response may to some extent be assay affected, since all Melmets grown as 
spheroids in the SFA (chapter 3.3) demonstrated a decreased RSF when treated with 
HGS-IgG compared to untreated cells. Still, different responses have been observed 
intra-experimentally, which could indicate a complex function of HGS-IgG, which 




The aim of the project was to investigate the expression of inhibitors of apoptosis 
(IAPs) and pro-apoptotic death receptors (DR4 and DR5) in malignant melanoma, 
since these proteins are important in the apoptotic pathway, and consequently, may 
have an impact on tumor initiation/progression and therapy efficiency. The second 
aim was to evaluate a treatment based on RNAi mediated down-regulation of IAPs 
combined with activators of apoptosis via DR4 and DR5 as an option for melanoma 
therapy in the future. The study was based on the comparison of two different 
melanoma cell models, i.e. monolayers versus spheroids. It has been reported that 
melanoma spheroid cells growing in stem cell media have higher abilities for tumor-
initiation in vivo (Fang et. al. and Prasmickaite, manuscript in preparation), 
supposedly due to the enhanced presence of melanoma CSC. Therefore, it is of 
importance to find a therapeutic strategy that could efficiently eliminate such cells. 
Characterization of melanoma spheroids with respect to expression of apoptosis -
related molecules, and evaluation of response to apoptosis-inducing therapy is, 
therefore, an important step in this direction. 
This study revealed that all Melmet models expressed IAPs (an exception was livin), 
and a tendency to increased IAP level was observed in spheroids compared to 
monolayers (8 out of 15 cases) (FIG. 3.3). Up-regulation of at least one IAP was 
observed in all Melmets grown as spheroids: Melmet 1 demonstrated an increased 
level of survivin and cIAP-2, Melmet 5 showed an increased level of livin and 
Melmet 79 had an elevated level of all five studied IAPs (FIG. 3.3). It should be 
mentioned that conclusions about the enhanced level of IAPs are based on western 
blotting data, while real-time PCR data were less conclusive, although they generally 
confirmed the above mentioned observations with a few exceptions. Since IAPs 
perform their so far known activity as proteins and not as mRNA, evaluation of the 
protein levels by western blotting is a reliable strategy and, therefore, was prioritized 
in this study.  
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Up-regulation of IAPs suggests that spheroid-derived melanoma cells might have 
elevated anti-apoptotic machinery (i.e. resistance). This fits well to the assumption 
that spheroids might be enriched for CSC. Furthermore, enhanced anti-apoptotic 
properties could contribute to the enhanced tumor-initiating abilities observed for 
spheroid cells as shown by Fang et. al. and Prasmickaite (FIG. 1.6). However, 
Melmet 79 spheroids showing up-regulation of all studied IAPs failed efficiently to 
initiate tumors in vivo (FIG. 1.6), indicating that IAPs probably are not a determining 
factor in tumor initiation. There are, however, several papers showing a correlation 
between IAP expression and tumor progression
62,55
.Thus, an elevated survivin level 
was shown to correlate with poor survival in melanoma
62,60
, suggesting that survivin 
could be a candidate to characterize aggressiveness in melanoma. In this context, it 
could be expected that aggressive melanoma cells that manage to establish metastases 
in vivo might have higher levels of IAPs. We, however, did not observe that in vivo 
metastases from tibia had an elevated level of IAPs compared to in vitro samples. An 
exception was livin, which was clearly up-regulated in the metastases from Melmet 5. 
Having in mind that livin was also strongly up-regulated in spheroids compared to 
monolayers, it would be of interest to investigate a role of livin in melanoma. Livin is  
also named melanoma-IAP, ML-IAP, because it is reported to be up-regulated in 
melanoma when compared to nevus
62,81
, but not to differ in level between primary 
and secondary melanoma
82
. This is also reflected by studies who invalidates livin as a 
prognostic factor in melanoma patients
59
. Additionally, the importance of livin in 
apoptosis are unclear, as demonstrated by antisense-mediated down-regulation of 
livin, which only induces apoptosis in some cell lines
83
, (Engesæter, unpublished 
data).    
All together, the IAPs studied revealed that Melmet cells, particularly from spheroids, 
express resistance-associated anti-apoptotic molecules, IAPs, which might be a 
hindrance in melanoma therapy aimed to induce apoptosis.  
One of the ways to stimulate apoptosis is through the death receptors (DR4 and 
DR5). To achieve a therapeutic benefit by strategies relaying on DR4 or DR5, the 
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target cells must express these receptors. Here we show that all Melmet models 
contain cells expressing DR4 and DR5. DR5 were expressed at a higher degree than 
DR4, which is in agreement to previous studies on fresh melanoma samples
44
. 
Furthermore, Melmets grown as spheroids had a slightly elevated level of DR4 and 
DR5 compared to Melmets grown as monolayer (FIG. 3.6), indicating that spheroid 
cells might be better targeted by TRAIL receptor Abs. Interestingly, DR4 and DR5 
are the only cell surface markers found so far to be up-regulated (particularly in the 
case of Melmet 1) in spheroids versus monolayers, while none of the potential CSC 
“markers” like CD133, ABCG2, CD20 or p75  showed this tendency (Prasmickaite, 
manuscript in preparation). Therefore, it is tempting to speculate that DR5 could be 
associated to tumor initiating cells in melanoma, since, e.g. Melmet 1 spheroids 
demonstrated high tumor initiating abilities in vivo (FIG. 1.6). It can be mentioned, 
however, that there were no clearly distinct DR4/DR5-positive and DR4/DR5-
negative subpopulations, and the majority of cells in population showed a similar 
expression of the receptors, which might complicate an employment of DR5 as a 
marker for CSC isolation. Rajeshkumar et. al. has already shown that DR5 up-
regulation is associated to pancreatic adenocarcinoma stem cells
84
. On the contrary, 
Zhuang et. al., has shown that a very high DR5 level in melanoma is correlated with 
good prognosis
44
, arguing against a possible link between DR5 and CSC. 
Although DR4/DR5 expression does not necessarily guarantee sensitivity to 
DR4/DR5 targeted therapy, cells without DR4/DR5 expression will certainly not be 
valid targets. Here we revealed that, despite the expression of DR4, all the Melmets 
showed a very weak (if any) response to HGS-ETR 1 (FIG. 3.7 and FIG. 3.8.). 
Additionally, we showed that the response to HGS-ETR 2 was medium/high in all 
Melmets, particularly in spheroids (FIG. 3.7 and FIG. 3.8). Treatment with HGS-ETR 
2 in Melmet monolayers resulted in 15%-60% reduction in cell viability, indicating 
that more than 40% of cells survived the treatment. The effect on the spheroids seem 
to be higher, where HGS-ETR 2 reduced spheroid formation by  50-95%, indicating 
that ≥ 5% of cells were not eliminated by the treatment, and are able to self-renew 
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and form spheres (i.e. candidate CSC). A higher response to HGS-ETR 2 in the 
spheroids than in the respective monolayers of Melmet 1 and Melmet 5 correlates to 
the increased DR5 expression in the spheroids (FIG. 3.10). Likewise, lower DR5 
expression in Melmet 79 spheroids corresponds to a lower response to the HGS-ETR 
2 treatment, indicating that the level of DR5 might be an important requirement for 
the efficiency of the treatment. Also, the lower/no effect of HGS-ETR 1 could be 
explained by lower DR4 expression, or, more unlikely, by low HGS-ETR 1 affinity 
towards DR4, given that the DR4 Ab has been proven to be effective in non-
melanoma cell lines (Engesæter, unpublished data). Additionally, DR4 and DR5 
glycosylation pattern or association with lipid rafts could possible control the cells 




It should be noted that also treatment with DTIC resulted in similar (low) efficiency 
in monolayers, as shown by Engesæter (FIG. 1.7), indicating that Melmet models 
harbour a large fraction of therapy-resistant cells.  
Limited sensitivity of Melmet cells to TRAIL receptor Abs suggest an active anti-
apoptotic mechanism
40
, which could be mediated by e.g. high levels of various IAPs 
as discussed above. Theoretically, down-regulation of IAPs could improve a 
therapeutic effect of the TRAIL receptor Abs. Therefore, two IAPs, survivin and 
XIAP, were selected for further studies, where the Melmet cells were transfected with 
anti-survivin or anti-XIAP siRNA. Combining the TRAIL receptor Abs and siRNA, 
we expected an additive or a synergistic effect. In monolayers, however, only Melmet 
79 showed an effect, where XIAP down-regulation contributed with additional 10% 
reduction of cell viability (additive effect), whereas no additional effect of anti -
survivin was observed (FIG. 3.17). In the spheroids, however, the down-regulation of 
anti-XIAP seems to have a more pronounced effect, reducing spheroid formation on 
average by 20% in all Melmets (FIG. 3.18). Altogether this indicates that contribution 
from siRNAs against XIAP or survivin under the conditions used in this study was 
quite low, and did not notably improve the efficiency of TRAIL receptor Abs. There 
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could be several explanations for lower than expected effect: i) the down-regulation 
was not efficient enough (see FIG. 3.14), and the remaining level of the IAP was still 
sufficient to perform an anti-apoptotic function. Further optimalization of the 
transfection is needed. ii) The other IAPs, not affected by the specific siRNA, “take 
over” apoptosis inhibition. In this respect, it would be of interest to combine several 
siRNA targeting different IAPs. iii) XIAP and survivin confer resistance to TRAIL 
receptor Ab-mediated apoptosis only in a small subpopulation of the cells, so that 
down-regulation of these IAPs does not considerably influence the sensitivity of the 
whole cell population.  
The observation that the Melmet spheroids often responded to the TRAIL receptor 
Abs more efficiently than the respective monolayers, might have important 
implications for melanoma therapy. Earlier it has been reported that, when grown as 
3D spheres, tumor cells demonstrate resistance to apoptosis inducible by e.g. TRAIL, 
which mimic the chemo resistance seen in solid tumors
87
. Therefore, there is an 
opinion that spheres are a better model for testing new therapeutic strategies, since 
they could reflect a more clinically relevant in vitro setting. Furthermore, as Fang et. 
al. and Prasmickaite demonstrated, melanoma cells from spheres seem to be more 
tumorigenic, thus representing a critical target in therapy. A response of Melmet 
spheroids to the TRAIL receptor Abs, particularly the response of Melmet 1 cells to 
the HGS-ETR 2, implies that these antibodies in combination with other drugs might 
be an interesting strategy for further evaluation, aiming to find a best combination for 
elimination of tumor initiating cells in malignant melanoma. Likely, cells with stem 
cell properties might constitute a quite large population, as shown in vivo by 
Quintana
21
 and in vitro by Prasmickaite (manuscript in preparation). The presence of 
a big fraction of stem cell-like melanoma cells could explain a generally low effect of 
treatments in Melmet models and signifies the importance of search for new 




All melanoma cell lines investigated in this study expressed survivin, XIAP, cIAP-1 
and cIAP-2 in vitro, and spheroids tended to have elevated IAP expression. Livin was 
also strongly up-regulated in spheroids in the two cell lines where livin expression 
was detected. HGS-ETR 1 hardly affected the melanoma cells survival. HGS-ETR 2 
induced an intermediate response, where down-regulation of XIAP, but not survivin, 
contributed with a small additive effect in some cases.  
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Future perspectives  
Designing new therapeutic strategies against cancer requires understanding of the 
biological mechanisms which sustain and promote tumor cell proliferation and 
resistance to cell death. In this study we have preformed an initial evaluation of the 
pro-apoptotic treatment including TRAIL receptor Ab and anti-IAP siRNA. The 
combination resulted in a limited effect, but technical improvements may increase the 
potency of the treatment. Further optimalization, like changing concentrations of 
various reagents used in the transfection protocol and varying cell numbers, may 
improve the IAP down-regulation. Since there is a possibility that one IAP could “fill 
in” the function of another IAP, a combined study targeting several IAPs at the same 
time, would perhaps be a more effective treatment strategy, than the single-IAP 
down-regulation used in this study. It will also be of interest to see the effect of anti-
livin treatment in respect to cell viability and spheroid formation, since livin was up-
regulated to a large extent when cells were grown as spheres or in vivo.  
Another interesting aspect is that some cells survive both TRAIL receptor Ab 
treatment and anti-IAP treatment. These therapy-resistant cells, which are able to 
form new spheres, should be investigated further in respect to survival mechanisms 
and stem cell markers. DR5 level could be interesting to study in relation to these 
therapy-resistant cells, as well as in relation to tumor initiating properties. This can be 
done by selecting DR5-high and DR5-low populations by flow cytometry, followed 
by seeding single cells into wells and evaluation of their in vitro spheroid forming 
capacity. If DR5-high cells produced significantly higher amount of spheroids than 
DR5-low cells, this difference in “tumorigenicity” may be studied further by a 
limiting dilution assay in vivo. Likewise, since survivin is related to outcome in 
melanoma patients, survivin positive/high cells could be interesting to evaluate 
against survivin negative/low cells, in respect to spheroid forming capacity.  
The therapeutic effect of TRAIL receptor Abs and anti-IAP treatment in this study 
was measured by cell viability assays and spheroid forming assays. Expanding the 
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panel of assays to include e.g. TUNEL, JC-1 and annexin staining or western blot of 
apoptotic markers, could evaluate if these effects actually is a result of the apoptotic 
process.  
In this study an experimental protocol for treatment of single melanoma cells in 3D 
format has been established. This procedure could be employed for testing the 
efficiency of various treatments, with the aim to identify, and eliminate, the 




Amidoblack solution: 1g Naphtol Blue Black, 450ml methanol, 100ml acetic acid and 
450ml ddH2O.  
BSN (Bjerrum – Scäfer – Nilsen) buffer 1X: 50ml 20X BSN (116g Tris, 58g glycin, 
ddH2O up to 1000ml.) and 950ml ddH2O. 
Destaining solution:  900ml methanol, 20ml acetic acid and 80ml ddH2O. 
Flow blocking buffer: PBS containing 0.5% FCS and 3% gammablocker. 
hESCM4 – human Embryonic Stem Cell Medium 4: 70% MEF conditioned media 
(hESC media used to culture MEF for 24hours), 30% hESC (80% DMEM-F12, 20% 
KnockOut Serum Replacer, 1% Non essential amino acids 100x, 2mM Glutamax and 
2.3% β-mercaptoethanol and 4ng/ml bFGF.) 
Loading buffer 6X: 15% SDS, 50% glycerol, 300mM Tris pH 6.8, 25% β-
mercaptoethanol, 0.6% Bromophenyl blue and ddH2O. 
Lysis solution: 1.5ml 5M NaCl, 5ml 0.5M Tris pH 7.5, 50µl NP_40 and ddH2O up to 
50ml. 
Lysis buffer: 960µl lysis solution, 10µl PMSF, 10µl Leupeptin, 10µl Pepstatin A and 
10µl Aprotinin. 
R&D buffer: 25ml 1M Tris pH 7.5, 30ml 5M NaCl, 1ml 20% Tween and ddH2O up 
to 1000ml. 
Running buffer 1X: 100ml Running buffer 10X ( 30.2g Tris, 144g glycin in 1L 
ddH2O), 5ml 20% SDS and ddH2O up to 1000ml. 
TBST – regular: 20ml 1M Tris pH7.5, 100ml 5M NaCl, 2.5ml Tween 20 and ddH2O 
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